# Patent

## Title
Moenomycin analogs, methods of synthesis, and uses thereof

## Abstract

The present invention provides compounds of Formula (I); or a pharmaceutically acceptable form thereof; wherein R1,R2,R3,R6,R7,R12,Ra, and Rb are as defined herein, and G is a group of Formula (a), (b), or (c): Formula (II), wherein X1; X2, X3, X4, X5, X6, X7, Y, RC, Rd, Rz, a, d, e, x, n, and m are as defined herein. The present invention further provides pharmaceutical compositions comprising a compound of Formula (I), kits comprising such compositions, methods of use and treatment, and preparative methods.

## Background
RELATED APPLICATIONS
The present application is a national stage filing under 35 U.S.C. §371 of international PCT application, PCT/US2013/035416, filed Apr. 5, 2013, which claims priority under 35 U.S.C. §119(e) to U.S. provisional patent application, U.S. Ser. No. 61/621,161, filed Apr. 6, 2012, each of which is incorporated herein by reference.


GOVERNMENT FUNDING
This invention was made with U.S. Government support under grant GM066174 awarded by the National Institutes of Health. The U.S. Government has certain rights in the invention.


BACKGROUND OF THE INVENTION
Bacteria have the ability to generate resistance to antibiotics through lateral gene transfer, mutation of enzymes, or the expression of enzymes which actively pump the antibiotic out of the cell or break it down. Over the past 10 years, resistance to existing antibiotics has become a significant problem in many countries. Vancomycin is currently the drug of last resort to combat multi-drug-resistant Gram-positive bacteria. In many places vancomycin-resistant Staphylococcus aureus and Enterococci (VRE) have been discovered. There is thus a desperate need for a new antibiotic drug to replace this drug of last resort.
There are a host of cytoplasmic targets for the development of new antibacterials, such as gyrase inhibitors, protein synthesis inhibitors, muramyl cascade inhibitors, and many more. The major hurdle in designing such drugs is that in addition to enzyme based activity these drugs need to cross the bacterial cell wall to exert their antibacterial effect. On the other hand, enzymes involved in synthesis of the bacterial cell wall exist on the cell wall exterior, and therefore drugs inhibiting these enzymes can exert their bactericidal or bacteriostatic effect without having to cross the cell wall. For example, penicillins, cephalosporins, and moenomycin are antibiotics that interact with bacterial transpeptidase enzymes. Vancomycin does not interact with bacterial transpeptidase enzymes but rather sequesters the substrate of the enzyme.
Moenomycin is the only known natural product that directly inhibits the synthesis of bacterial peptidoglycan (PG). The biological activity of moenomycin is remarkable compared with that of most other natural antibiotics: it is 10-1000 times more potent than vancomycin against Gram-positive organisms. See, e.g., Ostash and Walker, Curr. Opin. Chem. Biol. (2005) 9:459-466; Goldman et al., Curr. Med. Chem. (2000) 7:801-820. Structure-activity relationship studies of Moneomycin analogs conducted on the saccharide portion of the molecule have revealed that moenomycins with at least three carbohydrate units (C, E, and F) are active in vivo against Gram-positive bacteria. See, e.g., Garneau et al., Bioorganic & Medicinal Chemistry (2004) 12:6473-6494. Furthermore, while the phosporyl group and the carboxylate group of the phosphoglycerate linker are now considered important for bioactivity, the moenocinol chain is also considered to be an important structural component of the molecule and probably contributes to target binding both by direct interactions with the hydrophobic funnel that leads to the membrane and by membrane anchoring. See, e.g., Fuse et al., Chemical Biology (2010) 5:701-711. However, at the same time, the moenocinol chain is also credited with poor pharmacokinetic properties and high serum binding of meonomycin, e.g., its absorption upon oral administration is relatively poor. See, e.g., van Heijenoort, Glycobiology (2001) 11:25R-36R.




SUMMARY OF THE INVENTION
Previous work established that, although C10 analogues of the moenocinol chain are too short to retain biological activity, the C25 moenocinol chain of Moenomycin A is longer than required for activity. See, e.g., Ostash et al., Biochemistry (2009) 48:8830-8841. The inventors evaluated groups of intermediate length, structure, and hydrophobicity, e.g., C15-farnesyl, in an effort to explore the structure activity relationship (SAR) of the moenocinol chain. See, e.g., PCT Application Publication No. WO 2009/046314, incorporated herein by reference. The inventors now believe that groups with lengths greater than C15-farnesyl, chains substituted with halogen atoms, and chains comprising multiple aryl moieties, will provide increasingly more potent anti-bacterial compounds.
Thus, in one aspect, provided is a moenomycin A analog wherein the moenocinol chain is replaced with a group G, e.g., of the Formula (I),




or a pharmaceutically acceptable form thereof;

wherein Rings A, B, C and D of moenomycin A are optionally present, e.g., wherein RXX is hydrogen, a hydroxyl protecting group, or a group of Formula:





and R12 is hydrogen, a hydroxyl protecting group, or the group (D):





and wherein G is a group of Formula (a), (b), or (c):





wherein:

a is 3, 4, or 5;
X1, X2, X3, X4, X5, X6, and X7 are each independently hydrogen or halogen;
d is an integer between 1 and 25, inclusive;
e is an integer of between 2 and 25, inclusive;
provided the sum of d and e is greater than 16;
Y is —O—, —S—, —NRY—, or an optionally substituted methylene group, wherein RY is hydrogen, optionally substituted aliphatic, or an amino protecting group;
each instance of Rc is independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORe, —SRe, —NHRe, or —N(Re)2, wherein each instance of Re is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two Re groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;
each instance of Rd is independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORf, —SRf, —NHRf, or —N(Rf)2, wherein each instance of Rf is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two Rf groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;
Rz is hydrogen, —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORg, —SRg, —NHRg, or —N(Rg)2, wherein each instance of Rg is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl or two Rg groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;

    
    
        each instance of n is, independently, 0, 1, 2, 3, or 4;
        each instance of m is, independently, 0, 1, 2, 3, or 4; and
        x is 1, 2, 3, 4, 5, or 6;

wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R13, R14, R15, R16, R17, Ra, and Rb are as defined herein.

    
    


For example, in one embodiment of Formula (I), provided is a compound of Formula (II):




or a pharmaceutically acceptable form thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, Ra, and Rb are as defined herein, and G is a group of Formula (a), (b), or (c) as defined herein.

In another embodiment of Formula (I), provided is a compound of Formula (III):




or a pharmaceutically acceptable form thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8, R12, R17, Ra, and Rb are as defined herein, and G is a group of Formula (a, (b), or (c) as defined herein.

In yet another embodiment of Formula (I), provided is a compound of Formula (IV):




or a pharmaceutically acceptable form thereof; wherein R1, R2, R3, R6, R7, R12, R18, Ra, and Rb, are as defined herein, and G is a group of Formula (a), (b), or (c) as defined herein.

The present invention further provides pharmaceutical compositions comprising a compound of Formula (I), (II), (III), or (IV), and kits comprising such compositions. The present invention further provides methods of use and treatment, and preparative methods.
The details of one or more embodiments of the invention are set forth in the Detailed Description of Certain Embodiments, as described below. Other features, objects, and advantages of the invention will be apparent from the Definitions, Examples, and Claims.
DEFINITIONS
Definitions of specific functional groups and chemical terms are described in more detail below. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March March's Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; Carruthers, Some Modern Methods of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987; the entire contents of each of which are incorporated herein by reference.
The compounds of the present invention may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention.
Where an isomer/enantiomer is preferred, it may, in some embodiments, be provided substantially free of the corresponding enantiomer, and may also be referred to as “optically enriched.” “Optically enriched,” as used herein, means that the compound is made up of a significantly greater proportion of one enantiomer. In certain embodiments the compound of the present invention is made up of at least about 90% by weight of a preferred enantiomer. In other embodiments the compound is made up of at least about 95%, 98%, or 99% by weight of a preferred enantiomer. Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by asymmetric syntheses. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S. H., et al., Tetrahedron 33:2725 (1977); Eliel, E. L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, S. H. Tables of Resolving Agents and Optical Resolutions p. 268 (E. L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, Ind. 1972).
When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example, an “alkyl group having from 1 to 6 carbons” (also referred to herein as “C1-6 alkyl”) is intended to encompass 1 (C1 alkyl), 2 (C2 alkyl), 3 (C3 alkyl), 4 (C4 alkyl), 5 (C5 alkyl) and 6 (C6 alkyl) carbons, and a range of 1 to 6 (C1-6 alkyl), 1 to 5 (C1-5 alkyl), 1 to 4 (C1-4 alkyl), 1 to 3 (C1-3 alkyl), 1 to 2 (C1-2 alkyl), 2 to 6 (C2-6 alkyl), 2 to 5 (C2-5 alkyl), 2 to 4 (C2-4 alkyl), 2 to 3 (C2-3 alkyl), 3 to 6 (C3-6 alkyl), 3 to 5 (C3-5 alkyl), 3 to 4 (C3-4 alkyl), 4 to 6 (C4-6 alkyl), 4 to 5 (C4-5 alkyl), and 5 to 6 (C5-6 alkyl) carbons.
The term “aliphatic,” as used herein, refers to a monoradical of a non-aromatic, saturated or unsaturated, unbranched (“straight-chain”) or branched, substituted or unsubstituted, acyclic hydrocarbon having 1-50 carbon atoms (i.e., C1-50 aliphatic). Thus, as used herein, the term “aliphatic” encompasses the groups “alkyl”, “alkynyl”, and “alkenyl” as defined herein. In certain embodiments, aliphatic refers to a C2-C30 aliphatic group. In certain embodiments, aliphatic refers to a C5-C25 aliphatic group. In certain embodiments, aliphatic refers to a C1-C10 aliphatic group. In certain embodiments, aliphatic refers to a C10-C20 aliphatic group. In certain embodiments, aliphatic refers to a C11-C15 aliphatic group. Unless otherwise specified, each instance of aliphatic is independently unsubstituted (“unsubstituted aliphatic”) or substituted (“substituted aliphatic”) with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substituents as described herein. Aliphatic group substituents include, but are not limited to, any of the monovalent or divalent substituents described herein, that result in the formation of a stable moiety.
The term “alkyl,” as used herein, refers to a monoradical of a nonaromatic, saturated, unbranched (“straight-chain”) or branched, substituted or unsubstituted, acyclic hydrocarbon having 1-50 carbon atoms (i.e., C1-50 alkyl). In certain embodiments, alkyl refers to a C2-C30 alkyl group. In certain embodiments, alkyl refers to a C5-C25 alkyl group. In certain embodiments, alkyl refers to a C10-C20 alkyl group. In certain embodiments, alkyl refers to a C1-C10 alkyl group. In certain embodiments, alkyl refers to a C11-C15 alkyl group. Exemplary alkyl groups include, without limitation, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, sec-pentyl, iso-pentyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, sec-hexyl, n-heptyl, n-octyl, n-decyl, n-undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, and the like, which may bear one or more substituents. Unless otherwise specified, each instance of alkyl is independently unsubstituted (“unsubstituted alkyl”) or substituted (“substituted alkyl”) with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substituents as described herein. Alkyl group substituents include, but are not limited to, any of the monovalent or divalent substituents described herein, that result in the formation of a stable moiety.
“Methylene” refers to a divalent C1-alkyl group as defined herein.
The term “fluoroalkyl,” as used herein, refers to an alkyl group having from 1 to 50 carbon atoms wherein at least one hydrogen is replaced with a fluorine atom (“C1-50 fluoroalkyl”). In certain embodiments, the fluoroalkyl group has 1 to 8 carbon atoms (“C1-8 fluoroalkyl”). In certain embodiments, the fluoroalkyl group has 1 to 6 carbon atoms (“C1-6 fluoroalkyl”). In certain embodiments, the fluoroalkyl group has 1 to 4 carbon atoms (“C1-4 fluoroalkyl”). In certain embodiments, the fluoroalkyl group has 1 to 3 carbon atoms (“C1-3 fluoroalkyl”). In certain embodiments, the fluoroalkyl group has 1 to 2 carbon atoms (“C1-2 fluoroalkyl”). In certain embodiments, one hydrogen atom is replaced with a fluorine atom. In certain embodiments, two hydrogen atoms are replaced with fluorine atoms. In certain embodiments, three hydrogen atoms are replaced with fluorine atoms. In certain embodiments, four hydrogen atoms are replaced with fluorine atoms. In certain embodiments, five hydrogen atoms are replaced with fluorine atoms. In certain embodiments, all of the hydrogen atoms are replaced with fluorine atoms (also referred to as a “perfluoroalkyl” group). Exemplary fluoroalkyl groups include, but are not limited to, —CH2F, —CF2H, —CF3, —CH2CF3, —CF2CF3, —CH2CH2CF3, —CH2CF2CF3, —CF2CF2CF3, and the like.
The term “alkenyl,” as used herein, refers to a monoradical of a nonaromatic, unbranched (“straight-chain”) or branched, substituted or unsubstituted, acyclic hydrocarbon having at least one carbon-carbon double bond, having zero carbon-carbon triple bonds, and having 2-50 carbon atoms (i.e., C2-50 alkenyl). In certain embodiments, alkenyl refers to a C5-C25 alkenyl group. In certain embodiments, alkenyl refers to a C10-C20 alkenyl group. In certain embodiments, alkenyl refers to a C2-C10 alkenyl group. In certain embodiments, alkenyl refers to a C11-C15 alkenyl group. Exemplary alkenyl groups include, without limitation, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, and the like, which may bear one or more substituents. Unless otherwise specified, each instance of alkenyl is independently unsubstituted (“unsubstituted alkenyl”) or substituted (“substituted alkenyl”) with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substituents as described herein. Alkenyl group substituents include, but are not limited to, any of the monovalent or divalent substituents described herein, that result in the formation of a stable moiety.
The term “alkynyl,” as used herein, refers to a monoradical of a nonaromatic, unbranched (“straight-chain”) or branched, substituted or unsubstituted, acyclic hydrocarbon having at least one carbon-carbon triple bond, optionally containing one or more carbon-carbon double bonds, and having 2-50 carbon atoms (i.e., C2-50 alkynyl). In certain embodiments, alkynyl refers to a C5-C25 alkynyl group. In certain embodiments, alkynyl refers to a C2-C10 alkynyl group. In certain embodiments, alkynyl refers to a C10-C20 alkynyl group. In certain embodiments, alkynyl refers to a C11-C15 alkynyl group. Exemplary alkynyl groups include, without limitation, ethynyl, 2-propynyl(propargyl), 1-propynyl, and the like, which may bear one or more substituents. Unless otherwise specified, each instance of alkynyl is independently unsubstituted (“unsubstituted alkynyl”) or substituted (“substituted alkynyl”) with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substituents as described herein. Alkynyl group substituents include, but are not limited to, any of the monovalent or divalent substituents described herein, that result in the formation of a stable moiety.
The term “heteroaliphatic,” as used herein, refers to a C1-50 aliphatic group wherein one, two or three methylene units of the hydrocarbon chain are independently replaced with one or more oxygen, sulfur or nitrogen atoms. Thus, as used herein, the term “heteroaliphatic” encompasses the groups “heteroalkyl”, “heteroalkynyl”, and “heteroalkenyl” as defined herein. Unless otherwise specified, each instance of heteroaliphatic is independently unsubstituted (“unsubstituted heteroaliphatic”) or substituted (“substituted heteroaliphatic”) with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substituents as described herein. Heteroaliphatic group substituents include, but are not limited to, any of the monovalent or divalent substituents described herein, that result in the formation of a stable moiety.
The term “heteroalkyl,” as used herein, refers to a C1-50 alkyl group wherein one, two or three methylene units of the hydrocarbon chain are independently replaced with one or more oxygen, sulfur or nitrogen atoms. Unless otherwise specified, each instance of heteroalkyl is independently unsubstituted (“unsubstituted heteroalkyl”) or substituted (“substituted heteroalkyl”) with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substituents as described herein. Heteroalkyl group substituents include, but are not limited to, any of the monovalent or divalent substituents described herein, that result in the formation of a stable moiety.
The term “heteroalkenyl,” as used herein, refers to a C2-50 alkenyl group wherein one, two or three methylene units of the hydrocarbon chain are independently replaced with one or more oxygen, sulfur or nitrogen atoms. Unless otherwise specified, each instance of heteroalkenyl is independently unsubstituted (“unsubstituted heteroalkenyl”) or substituted (“substituted heteroalkenyl”) with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substituents as described herein. Heteroalkenyl group substituents include, but are not limited to, any of the monovalent or divalent substituents described herein, that result in the formation of a stable moiety.
The term “heteroalkynyl,” as used herein, refers to a C2-50 alkynyl group wherein one, two or three methylene units of the hydrocarbon chain are independently replaced with one or more oxygen, sulfur or nitrogen atoms. Unless otherwise specified, each instance of heteroalkynyl is independently unsubstituted (“unsubstituted heteroalkynyl”) or substituted (“substituted heteroalkynyl”) with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substituents as described herein. Heteroalkynyl group substituents include, but are not limited to, any of the monovalent or divalent substituents described herein, that result in the formation of a stable moiety.
The terms “carbocyclic” or “carbocyclyl,” as used herein, refer to a monoradical of a non-aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms (“C3-10 carbocyclyl”) and zero heteroatoms in the non-aromatic ring system. In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms (“C3-8 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C3-6 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C3-6 carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C5-10 carbocyclyl”). Exemplary C3-6 carbocyclyl groups include, without limitation, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6) and the like. Exemplary C3-8 carbocyclyl groups include, without limitation, the aforementioned C3-6 carbocyclyl groups as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), and the like. Exemplary C3-10 carbocyclyl groups include, without limitation, the aforementioned C3-8 carbocyclyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro-1H-indenyl (C9), decahydronaphthalenyl (C10), spiro[4.5]decanyl (C10) and the like. As the foregoing examples illustrate, in certain embodiments, the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or polycyclic (e.g., containing a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) or tricyclic system (“tricyclic carbocyclyl”)) and can be saturated or can contain one or more carbon-carbon double or triple bonds. “Carbocyclyl” also includes ring systems wherein the carbocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, as defined herein, wherein the point of attachment is on the carbocyclyl ring; in such instances, the number of carbons continues to designate the number of carbons in the carbocyclic ring system. Unless otherwise specified, each instance of a carbocyclyl group is independently unsubstituted (“unsubstituted carbocyclyl”) or substituted (“substituted carbocyclyl”) with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substituents as described herein. Carbocyclyl group substituents include, but are not limited to, any of the monovalent or divalent substituents described herein, that result in the formation of a stable moiety.
In some embodiments, “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 10 ring carbon atoms (“C3-10 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C3-8 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C3-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C5-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C5-10 cycloalkyl”). Exemplary C5-6 cycloalkyl groups include, without limitation, cyclopentyl (C5) and cyclohexyl (C5). Exemplary C3-6 cycloalkyl groups include, without limitation, the aforementioned C5-6 cycloalkyl groups as well as cyclopropyl (C3) and cyclobutyl (C4). Exemplary C3-8 cycloalkyl groups include, without limitation, the aforementioned C3-6 cycloalkyl groups as well as cycloheptyl (C7) and cyclooctyl (C8). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (“unsubstituted cycloalkyl”) or substituted (“substituted cycloalkyl”) with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substituents as described herein. Cycloalkyl group substituents include, but are not limited to, any of the monovalent or divalent substituents described herein, that result in the formation of a stable moiety.
The terms “heterocyclic” or “heterocyclyl,” as used herein, refer to a radical of a 3- to 14-membered nonaromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur (“3-14 membered heterocyclyl”). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or polycyclic (e.g., a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”) or tricyclic system (“tricyclic heterocyclyl”)), and can be saturated or can contain one or more carbon-carbon double or triple bonds. Heterocyclyl polycyclic ring systems can include one or more heteroatoms in one or both rings. “Heterocyclyl” includes ring systems wherein the heterocycyl ring, as defined above, is fused with one or more carbocycyl groups wherein the point of attachment is either on the carbocycyl or heterocyclyl ring; in such instances, the number of ring members continues to designate the number of ring members in the heterocyclyl ring system. Heterocycyl also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring; in such instances, the number of ring members continues to designate the number of ring members in the heterocyclyl ring system. In some embodiments, a heterocyclyl group is a 5-10 membered nonaromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur (“5-10 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5-8 membered nonaromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur (“5-8 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5-6 membered nonaromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur (“5-6 membered heterocyclyl”). In some embodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1 ring heteroatom selected from the group consisting of nitrogen, oxygen and sulfur. Exemplary 3-membered heterocyclyls containing 1 heteroatom include, without limitation, azirdinyl, oxiranyl, thiorenyl. Exemplary 4-membered heterocyclyls containing 1 heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl. Exemplary 5-membered heterocyclyls containing 1 heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyls containing 2 heteroatoms include, without limitation, dioxolanyl, oxathiolanyl and dithiolanyl. Exemplary 5-membered heterocyclyls containing 3 heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing 1 heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, dioxanyl. Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms include, without limitation, triazinanyl. Exemplary 7-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary bicyclic heterocyclyl groups include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, tetrahydrobenzothienyl, tetrahydrobenzofuranyl, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthyridinyl, decahydro-1,8-naphthyridinyl, octahydropyrrolo[3,2-b]pyrrole, indolinyl, phthalimidyl, naphthalimidyl, chromanyl, chromenyl, 1H-benzo[e][1,4]diazepinyl, 1,4,5,7-tetrahydropyrano[3,4-b]pyrrolyl, 5,6-dihydro-4H-furo[3,2-b]pyrrolyl, 6,7-dihydro-5H-furo[3,2-b]pyranyl, 5,7-dihydro-4H-thieno[2,3-c]pyranyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, 2,3-dihydrofuro[2,3-b]pyridinyl, 4,5,6,7-tetrahydro-1H-pyrrolo-[2,3-b]pyridinyl, 4,5,6,7-tetrahydrofuro[3,2-c]pyridinyl, 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl, 1,2,3,4-tetrahydro-1,6-naphthyridinyl, and the like. Unless otherwise specified, each instance of heterocyclyl is independently unsubstituted (“unsubstituted heterocyclyl”) or substituted (“substituted heterocyclyl”) with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substituents as described herein. Heterocyclyl group substituents include, but are not limited to, any of the monovalent or divalent substituents described herein, that result in the formation of a stable moiety.
The term “aryl,” as used herein, refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) aromatic ring system (e.g., having 6, 10 or 14π electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C6-14 aryl”). In some embodiments, an aryl group has 6 ring carbon atoms (“C6 aryl”; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms (“C10 aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms (“C14 aryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring; in such instances, the number of carbon atoms continues to designate the number of carbon atoms in the aryl ring system. Unless otherwise specified, each instance of an aryl group is independently unsubstituted (“unsubstituted aryl”) or substituted (“substituted aryl”) with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substituents as described herein. Aryl group substituents include, but are not limited to, any of the monovalent substituents described herein, that result in the formation of a stable moiety.
The terms “aralkyl” or “arylalkyl” are a subset of “alkyl” and refer to an alkyl group, as defined herein, substituted by an aryl group, as defined herein, wherein the point of attachment is on the alkyl moiety.
The term “heteroaryl,” as used herein, refers to a radical of a 5-14 membered monocyclic or polycyclic (e.g., bicyclic or tricyclic) aromatic ring system (e.g., having 6, 10 or 14π electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur (“5-14 membered heteroaryl”). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings. “Heteroaryl” includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocycyl or heterocycyl groups wherein the point of attachment is on the heteroaryl ring; in such instances, the number of ring members continues to designate the number of ring members in the heteroaryl ring system. “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or on the heteroaryl ring; in such instances, the number of ring members designates the number of ring members in the fused polycyclic (arylheteroaryl) ring system. For example, polycyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl and the like) the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl). In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur (“5-10 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur (“5-8 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur (“5-6 membered heteroaryl”). In some embodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from the group consisting of nitrogen, oxygen and sulfur. Exemplary 5-membered heteroaryls containing 1 heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary 5-membered heteroaryls containing 2 heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryls containing 3 heteroatoms include, without limitation, triazolyl, oxadiazolyl, thiadiazolyl. Exemplary 5-membered heteroaryls containing 4 heteroatoms include, without limitation, tetrazolyl. Exemplary 6-membered heteroaryls containing 1 heteroatom include, without limitation, pyridinyl. Exemplary 6-membered heteroaryls containing 2 heteroatoms include, without limitation, pyridazinyl, pyrimidinyl and pyrazinyl. Exemplary 6-membered heteroaryls containing 3 or 4 heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary 7 membered heteroaryls containing 1 heteroatom include, without limitation, azepinyl, oxepinyl and thiepinyl. Exemplary 5,6-bicyclic heteroaryls include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryls include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl and quinazolinyl. Exemplary tricyclic heteroaryls include, without limitation, phenanthridinyl, dibenzofuranyl, carbazolyl, acridinyl, phenothiazinyl, phenoxazinyl and phenazinyl. Unless otherwise specified, each instance of a heteroaryl group is independently unsubstituted (“unsubstituted heteroaryl”) or substituted (“substituted heteroaryl”) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substituents as described herein. Heteroaryl group substituents include, but are not limited to, any of the monovalent substituents described herein, that result in the formation of a stable moiety.
The terms “heteroarylalkyl” or “heteroaralkyl” are a subset of “alkyl” and refer to an alkyl group, as defined herein, substituted by a heteroaryl group, as defined herein, wherein the point of attachment is on the alkyl moiety.
As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aromatic groups (e.g., aryl or heteroaryl moieties) as defined herein.
Unless otherwise specified, aliphatic (e.g., alkyl, alkenyl, alkynyl), heteroaliphatic (e.g., heteroalkyl, heteroalkenyl, heteroalkynyl), carbocyclyl, heterocyclyl, aryl and heteroaryl groups, as defined herein, are optionally substituted (e.g., “substituted” or “unsubstituted” aliphatic, “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or “unsubstituted” heteroaliphatic, “substituted” or “unsubstituted” heteroalkyl, “substituted” or “unsubstituted” heteroalkenyl, “substituted” or “unsubstituted” heteroalkynyl, “substituted” or “unsubstituted” carbocyclyl, “substituted” or “unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl, or “substituted” or “unsubstituted” heteroaryl group). In general, the term “substituted” means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom etc.) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position.
Exemplary monovalent carbon atoms substituents include, but are not limited to, halo/halogen (i.e., —F, —Br, —Cl, —I), —NC, —CN, —NO2, —N3, —CO2H, —CHO, —SO2H, —SO3H, —S(═O)OH, acyl (e.g., —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA), amino (e.g., —NH2, —N(ORB)RB, —N(RB)2, —NRBSO2RA, —NRBC(═O)RA, —NRBCO2RA, —NRBC(═O)N(RB)2, —NRBC(═NRB)N(RB)2), thio (e.g., —SH, —SRA, —SSRB), oxy (e.g., —OH, —ORA, —ON(RB)2, —OSO2RA, —OS(═O)RA, —OC(═O)RA, —OCO2RA, —OC(═O)N(RB)2, —OC(═NRB)RA, —OC(═NRB)ORA, —OC(═NRB)N(RB)2), sulfonyl (e.g., —SO2RA, —SO2ORA, —SO2N(RB)2), sulfinyl (e.g., —S(═O)RA), silyl (e.g., —Si(RA)3), C1-10 alkyl, C1-10 fluoroalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, wherein each aliphatic, heteroaliphatic, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 RD groups;
each instance of RA is, independently, selected from the group consisting of C1-10 alkyl, C1-10 fluoroalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, wherein each aliphatic, heteroaliphatic, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 RD groups;
each instance of RB is, independently, selected from the group consisting of hydrogen, —OH, —ORA, —N(RC)2, —CN, —C(═O)RA, —C(═O)N(RC)2, —CO2RA, —SO2RA, —C(═NRC)ORA, —C(═NRC)N(RC)2, —SO2N(RC)2, —SO2RC, —SO2ORC, —SORA, —C(═S)N(RC)2, —C(═O)SRC, —C(═S)SRC, C1-10 alkyl, C1-10 fluoroalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RB groups attached to an N atom are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each aliphatic, heteroaliphatic, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 RD groups;
each instance of RC is, independently, selected from the group consisting of hydrogen, C1-10 alkyl, C1-10 fluoroalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RC groups attached to an N atom are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each aliphatic, heteroaliphatic, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 RD groups; and
each instance of RD is, independently, halogen, —CN, —NO2, —N3, —SO2H, —SO3H, —OH, —OC1-6 alkyl, —ON(C1-6 alkyl)2, —N(C1-6 alkyl)2, —N(OC1-6 alkyl)(C1-6 alkyl), —N(OH)(C1-6 alkyl), —NH(OH), —SH, —SC1-6 alkyl, —SS(C1-6 alkyl), —C(═O)(C1-6 alkyl), —CO2H, —CO2(C1-6 alkyl), —OC(═O)(C1-6 alkyl), —OCO2(C1-6 alkyl), —C(═O)NH2, —C(═O)N(C1-6 alkyl)2, —OC(═O)NH(C1-6 alkyl), —NHC(═O)(C1-6 alkyl), —N(C1-6 alkyl)C(═O)(C1-6 alkyl), —NHCO2(C1-6 alkyl), —NHC(═O)N(C1-6 alkyl)2, —NHC(═O)NH(C1-6 alkyl), —NHC(═O)NH2, —C(═NH)O(C1-6 alkyl), —OC(═NH)(C1-6alkyl), —OC(═NH)OC1-6alkyl, —C(═NH)N(C1-6alkyl)2, —C(═NH)NH(C1-6 alkyl), —C(═NH)NH2, —OC(═NH)N(C1-6 alkyl)2, —OC(NH)NH(C1-6 alkyl), —OC(NH)NH2, —NHC(NH)N(C1-6 alkyl)2, —NHC(═NH)NH2, —NHSO2(C1-6 alkyl), —SO2N(C1-6 alkyl)2, —SO2NH(C1-6 alkyl), —SO2NH2, —SO2C1-6 alkyl, —SO2OC1-6 alkyl, —OSO2C1-6 alkyl, —S(═O)C1-6 alkyl, C1-6 alkyl, C1-6 fluoroalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 carbocyclyl, C6-10 aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl; or two geminal RD substituents are joined to form ═O, ═S or ═NRB.
Exemplary divalent carbon atom substituents include, but are not limited to ═O, ═S, and ═NRB, wherein RB is as defined herein.
Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary and quarternary nitrogen atoms. Exemplary nitrogen atom substituents include, but are not limited to, ═NRB, —CHO, —C(═O)RA, —CO2RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —NH2, —N(ORB)RB, —N(RB)2, —NRBSO2RA, —NRBC(═O)RA, —NRBCO2RA, —NRBC(═O)N(RB)2, —NRBC(═NRB)N(RB)2, —OH, —ORA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA), —Si(RA)3, C1-10 alkyl, C1-10 fluoroalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 RD groups.
In certain embodiments, nitrogen atom substituents, as described above, are also referred to as “amino protecting groups” or “nitrogen protecting groups”. Amino protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference.
Exemplary amino protecting groups include, but are not limited to, methyl carbamate, ethyl carbamate, acetyl (—C(═O)CH3, —Ac), 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethyl carbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate, 1,1-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1-methyl-1-(4-biphenylyl)ethyl carbamate (Bpoc), 1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate (t-Bumeoc), 2-(2′- and 4′-pyridyl)ethyl carbamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc), 1,1-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, phenothiazinyl-(10)-carbonyl derivative, N′-p-toluenesulfonylaminocarbonyl derivative, N′-phenylaminothiocarbonyl derivative, t-amyl carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxycarbonylvinyl carbamate, o-(N,N-dimethylcarboxamido)benzyl carbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p′-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1-methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, 2,4,6-trimethylbenzyl carbamate, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide, o-nitophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N′-dithiobenzyloxycarbonylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine derivative, o-nitrobenzamide, o-(benzoyloxymethyl)benzamide, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridone, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4-nitro-2-oxo-3-pyroolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm), N-2-picolylamino N′-oxide, N-1,1-dimethylthiomethyleneamine, N-benzylideneamine, N-p-methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, N(N′,N′-dimethylaminomethylene)amine, N,N′-isopropylidenediamine, N-p-nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine, N-borane derivative, N-diphenylborinic acid derivative, N-[phenyl(pentacarbonylchromium- or tungsten)carbonyl]amine, N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, 3-nitropyridinesulfenamide (Npys), p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6,-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4′,8′-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.
Exemplary oxygen substituents include, but are not limited to, —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA, —Si(RA)3, —C1-10 alkyl, C1-10 fluoroalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 RD groups.
In certain embodiments, oxygen atom substituents, as described above, are also referred to as “hydroxyl protecting groups” or “oxygen protecting groups”. Hydroxyl protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference.
Exemplary hydroxyl protecting groups include, but are not limited to, acetyl (—C(═O)CH3, —Ac), methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP), 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxido, diphenylmethyl, p,p′-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, α-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4′-bromophenacyloxyphenyl)diphenylmethyl, 4,4′,4′′-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4′,4′′-tris(levulinoyloxyphenyl)methyl, 4,4′,4′′-tris(benzoyloxyphenyl)methyl, 3-(imidazol-1-yl)bis(4′,4′′-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-1′-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1,3-benzodithiolan-2-yl, benzisothiazolyl S,S-dioxido, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t-butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate (mesitoate), methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), ethyl carbonate, 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl)ethyl carbonate (Psec), 2-(triphenylphosphonio)ethyl carbonate (Peoc), isobutyl carbonate, vinyl carbonate, allyl carbonate, p-nitrophenyl carbonate, benzyl carbonate, p-methoxybenzyl carbonate, 3,4-dimethoxybenzyl carbonate, o-nitrobenzyl carbonate, p-nitrobenzyl carbonate, S-benzyl thiocarbonate, 4-ethoxylnapththyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate, o-(methoxycarbonyl)benzoate, α-naphthoate, N,N,N′,N′-tetramethylphosphorodiamidate, N-phenylcarbamate, dimethylphosphinothioyl, 2,4-dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts). For protecting 1,2- or 1,3-diols, the protecting groups include methylene acetal, ethylidene acetal, 1-t-butylethylidene ketal, 1-phenylethylidene ketal, (4-methoxyphenyl)ethylidene acetal, 2,2,2-trichloroethylidene acetal, acetonide, cyclopentylidene ketal, cyclohexylidene ketal, cycloheptylidene ketal, benzylidene acetal, p-methoxybenzylidene acetal, 2,4-dimethoxybenzylidene ketal, 3,4-dimethoxybenzylidene acetal, 2-nitrobenzylidene acetal, methoxymethylene acetal, ethoxymethylene acetal, dimethoxymethylene ortho ester, 1-methoxyethylidene ortho ester, 1-ethoxyethylidine ortho ester, 1,2-dimethoxyethylidene ortho ester, α-methoxybenzylidene ortho ester, 1-(N,N-dimethylamino)ethylidene derivative, α-(N,N′-dimethylamino)benzylidene derivative, 2-oxacyclopentylidene ortho ester, di-t-butylsilylene group (DTBS), 1,3-(1,1,3,3-tetraisopropyldisiloxanylidene) derivative (TIPDS), tetra-t-butoxydisiloxane-1,3-diylidene derivative (TBDS), cyclic carbonates, cyclic boronates, ethyl boronate, and phenyl boronate.
The term “pharmaceutically acceptable form thereof” as used herein refers to pharmaceutically acceptable salts, solvates, hydrates, prodrugs, tautomers, isomers, enantiomers, diastereomers, and/or polymorphs of a compound of the present invention.
In certain embodiments, the pharmaceutically acceptable form is a pharmaceutically acceptable salt. The term “pharmaceutically acceptable salt” as used herein refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1-4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
In certain embodiments, the pharmaceutically acceptable form is a hydrate or solvate. The term “hydrate” as used herein refers to a compound non-covalently associated with one or more molecules of water. Likewise, the term “solvate” refers to a compound non-covalently associated with one or more molecules of an organic solvent.
In certain embodiments, the pharmaceutically acceptable form is a prodrug. The term “prodrug” as used herein refers to a derivative of a parent compound that requires transformation within the body in order to release the parent compound. In certain cases, a prodrug has improved physical and/or delivery properties over the parent compound. Prodrugs are typically designed to enhance pharmaceutically and/or pharmacokinetically based properties associated with the parent compound. The advantage of a prodrug can lie in its physical properties, such as enhanced water solubility for parenteral administration at physiological pH compared to the parent compound, or it enhances absorption from the digestive tract, or it may enhance drug stability for long-term storage. In recent years several types of bioreversible derivatives have been exploited for utilization in designing prodrugs. Using esters as a prodrug type for compounds containing a carboxyl or hydroxyl functionality is known in the art as described, for example, in The Organic Chemistry of Drug Design and Drug Interaction by Richard Silverman, published by Academic Press (1992).
In certain embodiments, the pharmaceutically acceptable form is a tautomer. The term “tautomer” as used herein includes two or more interconvertable compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valency (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa). The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Tautomerizations (i.e., the reaction providing a tautomeric pair) may catalyzed by acid or base. Exemplary tautomerizations include keto-to-enol; amide-to-imide; lactam-to-lactim; enamine-to-imine; and enamine-to-(a different) enamine tautomerizations.
In certain embodiments, the pharmaceutically acceptable form is an isomer. The term “isomer” as used herein includes any and all geometric isomers and stereoisomers (e.g., enantiomers, diasteromers, etc.). For example, “isomer” include cis- and trans-isomers, E- and Z-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. For instance, an isomer/enantiomer may, in some embodiments, be provided substantially free of the corresponding enantiomer, and may also be referred to as “optically enriched.” “Optically-enriched,” as used herein, means that the compound is made up of a significantly greater proportion of one enantiomer. In certain embodiments the compound of the present invention is made up of at least about 90% by weight of a preferred enantiomer. In other embodiments the compound is made up of at least about 95%, 98%, or 99% by weight of a preferred enantiomer. Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by asymmetric syntheses. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S. H., et al., Tetrahedron 33:2725 (1977); Eliel, E. L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, S. H. Tables of Resolving Agents and Optical Resolutions p. 268 (E. L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, Ind. 1972).
In certain embodiments, the pharmaceutically acceptable form is a polymorph. The term “polymorph” as used herein refers to a crystalline compound existing in more than one crystalline form/structure. When polymorphism exists as a result of difference in crystal packing it is called packing polymorphism. Polymorphism can also result from the existence of different conformers of the same molecule in conformational polymorphism. In pseudopolymorphism the different crystal types are the result of hydration or solvation.
A “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and/or other primates (e.g., cynomolgus monkeys, rhesus monkeys); mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs; and/or birds, including commercially relevant birds such as chickens, ducks, geese, and/or turkeys.
As used herein, the terms “treat,” “treating” and “treatment” refer to partially or completely halting, reducing, delaying, or diminishing the severity of an infection or symptoms related to an infection from which the subject is suffering.
As used herein, the terms “prevent,” “preventing” and “prevention” contemplate an action that occurs before a subject begins to suffer an infection or symptoms related to an infection.
As used herein “inhibition,” “inhibiting,” and “inhibit”, refer to the ability of a compound to reduce, slow, halt or prevent activity of a particular biological process in a cell relative to vehicle. In certain embodiments, the biological process is in vitro (e.g., cellular assay). In certain embodiments, the biological process is in vivo.
As used herein, and unless otherwise specified, an “effective amount” refers to the minimal amount or concentration of an inventive compound or pharmaceutical composition thereof that, when administered, is sufficient in treating or preventing an infection in the subject. In certain embodiments of the present invention an “effective amount” of the inventive compound or pharmaceutical composition thereof is that amount effective for killing, inhibiting, or preventing, the growth of the causative microbial organism (e.g., a bacterium, virus, parasite, or fungus). In certain embodiments, an effective amount is the amount administered to a subject to achieve a concentration at the site of infection sufficient to inhibit the growth of the causative microbial organism. In certain embodiments, an effective amount is the amount administered to a subject to achieve the mean inhibitory concentration at the site of infection for the causative microbial organism.
As used herein, and unless otherwise specified, a “therapeutically effective amount” of a compound is an amount sufficient to provide a therapeutic benefit in the treatment of a infection or to delay or minimize one or more symptoms associated with the infection. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the infection. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of infection, or enhances the therapeutic efficacy of another therapeutic agent.
As used herein, and unless otherwise specified, a “prophylactically effective amount” of a compound is an amount sufficient to prevent an infection, or one or more symptoms associated with the infection or prevent its recurrence. A prophylactically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the infection. The term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
As used herein, “infection” refers to a microbial infection (i.e., a bacterial infection, a viral infection, a parasitic infection, or a fungal infection). In certain embodiments, the infection is a bacterial infection.


DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION
Moenomycin A is a natural product that inhibits peptidoglycan biosynthesis by binding to bacterial transglycosylases. Moenomycin A is a thousand times more potent than the antibiotic vancomycin, but poor pharmacokinetic properties related to the lipid side chain have prevented its use in humans. Removal of the natural lipid side chain completely abolishes biological activities. A comprehensive study of the effect of different side chains, optionally in combination with different sugar portions, on the antibacterial activity compared to natural moenomycin A, has been limited as most synthetic tranformations employed in the removal of the natural lipid side chain and in the addition of other different side chains have also altered other structural features of the molecule. Recently, a mild, semi-synthetic, methodology was disclosed which enabled SAR study of new moenomycins; e.g., see PCT Application Publication No. WO 2009/046314, incorporated herein by reference. In the '314 publication, the inventors explored groups of intermediate length and hydrophobicity, e.g., C15-farnesyl, in an effort to explore the optimal length for activity and bioavailability. The inventors now believe that groups with lengths greater than C15-farnesyl, chains substituted with halogen atoms, and chains comprising multiple aryl moieties, will provide increasingly more potent anti-bacterial compounds.
In particular, the present invention is directed to noenomycin A analogs wherein the moenocinol chain is replaced with a group G, e.g., of the Formula (I),




or a pharmaceutically acceptable form thereof;

wherein Rings A, B, C and D of moenomycin A are optionally present, e.g., wherein RXX is hydrogen, a hydroxyl protecting group, or a group of Formula:





and R12 is hydrogen, a hydroxyl protecting group, or the group (D):





and wherein G is a group of Formula (a), (b), or (C):





wherein:

    
    
        a is 3, 4, or 5;
        X1, X2, X3, X4, X5, X6, and X7 are each independently hydrogen or halogen;
        d is an integer between 1 and 25, inclusive;
        e is an integer of between 2 and 25, inclusive;
        provided the sum of d and e is greater than 16;
        Y is —O—, —S—, —NRY—, or an optionally substituted methylene group, wherein RY is hydrogen, optionally substituted aliphatic, or an amino protecting group;
        each instance of Rc is independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORe, —SRe, —NHRe, or —N(Re)2, wherein each instance of Re is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two Re groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;
        each instance of Rd is independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORf, —SRf, —NHRf, or —N(Rf)2, wherein each instance of Rf is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two Rf groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;
        Rz is hydrogen, —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORg, —SRg, —NHRg, or —N(Rg)2, wherein each instance of Rg is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl or two Rg groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;
        each instance of n is, independently, 0, 1, 2, 3, or 4;
        each instance of m is, independently, 0, 1, 2, 3, or 4; and
        x is 1, 2, 3, 4, 5, or 6;

and wherein R1, R2, R3, R4R5, R6, R7, R8, R9, R10, R11, R13, R14, R15, R16, R17, Ra, and Rb are as defined herein.

    
    


In certain embodiments, the present invention provides compounds wherein the sugar portion comprising Rings C, E and F, and optionally Rings A, B, and D, is derived from moenomycin A. In certain embodiments, Rings A, B and/or D are enzymatically or chemically cleaved to provide such compounds. In other embodiments, intermediate moenomycin-like compounds (e.g., without Rings A, B, and/or D) are generated from bacteria (e.g., wild type or genetically engineered bacteria) and further sythetically modified to provide compounds of the present invention.
Compounds encompassed by the present invention, e.g., compounds of the Formula (II), (III), and (IV), are described in more detail herein.
Compounds of Formula (II)
The present invention further provides compounds of Formula (II), as provided below, which include compounds comprising Rings B, C, E and F, and optionally Rings A and D, of the moenomycin A sugar scaffold.
In one aspect, the present invention provides a compound of Formula (II):




or a pharmaceutically acceptable form thereof;

wherein:

    
    
        R1, R2, R3, and R4 are each independently hydrogen or an amino protecting group;
        R5 is hydrogen, an amino protecting group, or the group (A):
    
    






    
    
        R6, R7, R8, R9, R10, and R11 are each independently hydrogen or a hydroxyl protecting group;
        R12 is hydrogen, a hydroxyl protecting group, or the group (D):
    
    






    
    
        wherein R13, R14, R15, and R16 are each independently hydrogen or a hydroxyl protecting group;
        Ra and Rb are each independently hydrogen or a hydroxyl protecting group; and wherein G is a group of Formula (a), (b), or (c) as defined herein.
    
    


As generally defined above, R1, R2, R3, and R4 are each independently hydrogen or an amino protecting group Amino protecting groups are defined herein, and include, but are not limited to, —CHO, —C(═O)RA, —CO2RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —NH2, —N(ORB)RB, —N(RB)2, —NRBSO2RA, —NRBC(═O)RA, —NRBCO2RA, —NRBC(═O)N(RB)2, —NRBC(═NRB)N(RB)2, —OH, —ORA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA), —Si(RA)3, C1-10 alkyl, C1-10 fluoroalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 RD groups, wherein RA, RB, and RD are as defined herein.
In certain embodiments, R1 is hydrogen, —C(═O)RA, —CO2RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA), or —Si(RA)3, wherein RA and RB are as defined herein. In certain embodiments, R1 is hydrogen or —C(═O)RA, wherein RA is as defined herein. In certain embodiments, R1 is hydrogen or —C(═O)RA, wherein RA is C1-10 alkyl. In certain embodiments, R1 is hydrogen or —C(═O)RA, wherein RA is C1-6 alkyl. In certain embodiments, R1 is hydrogen or —C(═O)CH3. In certain embodiments, R1 is hydrogen. In certain embodiments, R1 is —C(═O)CH3.
In certain embodiments, R2 is hydrogen, —C(═O)RA, —CO2RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA), or —Si(RA)3, wherein RA and RB are as defined herein. In certain embodiments, R2 is hydrogen or —C(═O)RA, wherein RA is as defined herein. In certain embodiments, R2 is hydrogen or —C(═O)RA, wherein RA is C1-10 alkyl. In certain embodiments, R2 is hydrogen or —C(═O)RA, wherein RA is C1-6 alkyl. In certain embodiments, R2 is hydrogen or —C(═O)CH3. In certain embodiments, R2 is hydrogen. In certain embodiments, R2 is —C(═O)CH3.
In certain embodiments, R3 is hydrogen, —C(═O)RA, —CO2RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA), or —Si(RA)3, wherein RA and RB are as defined herein. In certain embodiments, R3 is hydrogen or —C(═O)RA, wherein RA is as defined herein. In certain embodiments, R3 is hydrogen or —C(═O)RA, wherein RA is C1-10 alkyl. In certain embodiments, R3 is hydrogen or —C(═O)RA, wherein RA is C1-6 alkyl. In certain embodiments, R3 is hydrogen or —C(═O)CH3. In certain embodiments, R3 is hydrogen. In certain embodiments, R3 is —C(═O)CH3.
In certain embodiments, R4 is hydrogen, —C(═O)RA, —CO2RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA), and —Si(RA)3, wherein RA and RB are as defined herein. In certain embodiments, R4 is hydrogen or —C(═O)RA, wherein RA is as defined herein. In certain embodiments, R4 is hydrogen or —C(═O)RA, wherein RA is C1-10 alkyl. In certain embodiments, R4 is hydrogen or —C(═O)RA, wherein RA is C1-6 alkyl. In certain embodiments, R4 is hydrogen or —C(═O)CH3. In certain embodiments, R4 is hydrogen. In certain embodiments, R4 is —C(═O)CH3.
As defined generally above, R5 is hydrogen, an amino protecting group, or the group (A). Amino protecting groups are defined herein, e.g., —CHO, —C(═O)RA, —CO2RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —NH2, —N(ORB)RB, —N(RB)2, —NRBSO2RA, —NRBC(═O)RA, —NRBCO2RA, —NRBC(═O)N(RB)2, —NRBC(═NRB)N(RB)2, —OH, —ORA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA), —Si(RA)3, C1-10 alkyl, C1-10 fluoroalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 RD groups, wherein RA, RB, and RD are as defined herein.
In certain embodiments, R5 is hydrogen, —C(═O)RA, —CO2RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA), and —Si(RA)3, wherein RA and RB are as defined herein, or the group (A).
In certain embodiments, R5 is hydrogen or —C(═O)RA wherein RA is as defined herein, or the group (A).
In certain embodiments, R5 is hydrogen or the group (A).
In certain embodiments, R5 is hydrogen.
In certain embodiments, R5 is the group (A).
As defined generally above, R6, R7, R8, R9, R10, and R11 are each independently hydrogen or a hydroxyl protecting group. Hydroxyl protecting groups are defined herein, and include, but are not limited to, —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA, —Si(RA)3, C1-10 alkyl, C1-10 fluoroalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 RD groups, wherein RA, RB, and RD are as defined herein.
In certain embodiments, R6 is hydrogen, —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA, and —Si(RA)3, wherein RA and RB are as defined herein. In certain embodiments, R6 is hydrogen or —C(═O)RA, wherein RA is as defined herein. In certain embodiments, R6 is hydrogen or —C(═O)RA, wherein RA is C1-10 alkyl. In certain embodiments, R6 is hydrogen or —C(═O)RA, wherein RA is C1-6 alkyl. In certain embodiments, R6 is hydrogen or —C(═O)CH3. In certain embodiments, R6 is hydrogen. In certain embodiments, R6 is —C(═O)CH3.
In certain embodiments, R7 is hydrogen, —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA, or —Si(RA)3, wherein RA and RB are as defined herein. In certain embodiments, R7 is hydrogen or —C(═O)RA, wherein RA is as defined herein. In certain embodiments, R7 is hydrogen or —C(═O)RA, wherein RA is C1-10 alkyl. In certain embodiments, R7 is hydrogen or —C(═O)RA, wherein RA is C1-6 alkyl. In certain embodiments, R7 is hydrogen or —C(═O)CH3. In certain embodiments, R7 is hydrogen. In certain embodiments, R7 is —C(═O)CH3.
In certain embodiments, R8 is hydrogen, —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA, or —Si(RA)3, wherein RA and RB are as defined herein. In certain embodiments, R8 is hydrogen or —C(═O)RA, wherein RA is as defined herein. In certain embodiments, R8 is hydrogen or —C(═O)RA, wherein RA is C1-10 alkyl. In certain embodiments, R8 is hydrogen or —C(═O)RA, wherein RA is C1-6 alkyl. In certain embodiments, R8 is hydrogen or —C(═O)CH3. In certain embodiments, R8 is hydrogen. In certain embodiments, R8 is —C(═O)CH3.
In certain embodiments, R9 is hydrogen, —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA, or —Si(RA)3, wherein RA and RB are as defined herein. In certain embodiments, R9 is hydrogen or —C(═O)RA, wherein RA is as defined herein. In certain embodiments, R9 is hydrogen or —C(═O)RA, wherein RA is C1-10 alkyl. In certain embodiments, R9 is hydrogen or —C(═O)RA, wherein RA is C1-6 alkyl. In certain embodiments, R9 is hydrogen or —C(═O)CH3. In certain embodiments, R9 is hydrogen. In certain embodiments, R9 is —C(═O)CH3.
In certain embodiments, R10 is hydrogen, —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA, or —Si(RA)3, wherein RA and RB are as defined herein. In certain embodiments, R10 is hydrogen or —C(═O)RA, wherein RA is as defined herein. In certain embodiments, R10 is hydrogen or —C(═O)RA, wherein RA is C1-10 alkyl. In certain embodiments, R10 is hydrogen or —C(═O)RA, wherein RA is C1-6 alkyl. In certain embodiments, R10 is hydrogen or —C(═O)CH3. In certain embodiments, R10 is hydrogen. In certain embodiments, R10 is —C(═O)CH3.
In certain embodiments, R11 is hydrogen, —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA, or —Si(RA)3, wherein RA and RB are as defined herein. In certain embodiments, R11 is hydrogen or —C(═O)RA, wherein RA is as defined herein. In certain embodiments, R11 is hydrogen or —C(═O) RA, wherein RA is C1-10 alkyl. In certain embodiments, R11 is hydrogen or —C(═O)RA, wherein RA is C1-6 alkyl. In certain embodiments, R11 is hydrogen or —C(═O)CH3. In certain embodiments, R10 is hydrogen. In certain embodiments, R11 is —C(═O)CH3.
In certain embodiments, R1, R2, R3, R4, R6, R7, R8, R9, R10 and R11 are each independently hydrogen or —C(═O)RA, wherein RA is as defined herein.
In certain embodiments, R1 and R2 are each hydrogen.
In certain embodiments, R3 and R4 are each —C(═O)RA, wherein RA is as defined herein. In certain embodiments, R3 and R4 are each —C(═O)CH3.
In certain embodiments, R6, R7, R8, R9, R10 and R11 are each hydrogen.
As generally defined above, R12 is hydrogen, a hydroxyl protecting group, or the group (D), wherein R13, R14, R15, and R16 are each independently hydrogen or a hydroxyl protecting group. Hydroxyl protecting groups are defined herein, and include, but are not limited to, —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA, —Si(RA)3, C1-10 alkyl, C1-10 fluoroalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 RD groups, wherein RA, RB, and RD are as defined herein.
In certain embodiments, R12 is hydrogen, —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA, and —Si(RA)3, wherein RA and RB are as defined herein, or the group (D), wherein R13, R14,R15, and R16 are each independently —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA, or —Si(RA)3, wherein RA and RB are as defined herein.
In certain embodiments, R12 is hydrogen, —C(═O)RA, or the group (D), wherein R13, R14, R15, and R16 are each independently hydrogen or —C(═O)RA, and wherein RA is as defined herein.
In certain embodiments, R12 is hydrogen, —C(═O)CH3 or the group (D), wherein R13, R14, R15, and R16 are each independently hydrogen or —C(═O)CH3.
In certain embodiments, R12 is hydrogen. In certain embodiments, R12 is —C(═O)CH3.
In certain embodiments, R12 is the group (D), wherein R13, R14, R15, and R16 are each independently hydrogen or —C(═O)CH3. In certain embodiments, R13, R14, R15, and R16 are each hydrogen.
As generally defined above, Ra and Rb are each independently hydrogen or a hydroxyl protecting group. Hydroxyl protecting groups are defined herein, and include, but are not limited to, —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA, —Si(RA)3, C1-10 alkyl, C1-10 fluoroalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 RD groups, wherein RA, RB, and RD are as defined herein.
In certain embodiments, Ra and Rb are each independently hydrogen or C1-10 alkyl. In certain embodiments, Ra and Rb are each independently hydrogen or C1-6 alkyl. In certain embodiments, Ra and Rb are each independently hydrogen or —CH3. In certain embodiments, Ra is hydrogen. In certain embodiments, Rb is hydrogen. In certain embodiments, both Ra and Rb are hydrogen.
In certain embodiments, Ra, Rb, R1, R2, R6, R7, R8, R9, R10 and R11 are each hydrogen, and R3 and R4 are each —C(═O)CH3.
In certain embodiments, Ra, Rb, R1, R2, R6, R7, R8, R9, R10 and R11 are each hydrogen, R3 and R4 are each —C(═O)CH3, R5 is the group (A), and R12 is the group (D) wherein R13, R14, R15, and R16 are each hydrogen.
Various sub-genera of Formula (II) are further described herein. For example, in certain embodiments, the compound of Formula (II) is a compound of Formula (II-a):




or a pharmaceutically acceptable form thereof; wherein G, R5, and R12 are as defined herein.

In certain embodiments the compound of Formula (II) is a compound of Formula (II-b):




or a pharmaceutically acceptable form thereof; wherein G is as defined herein.

Compounds of Formula (III)

The present invention further provides compounds of Formula (III), as provided below, which include compounds comprising Rings C, E and F, and optionally Ring D, of the moenomycin A sugar scaffold.
For example, in one aspect, the present invention provides a compound of Formula (III):




or a pharmaceutically acceptable form thereof; wherein R1, R2, R3, R4, R6, R7, R8, R12, Ra, and Rb, are as defined above and herein; G is a group of Formula (a), (b), or (c) as defined above and herein; and R17 is hydrogen or a hydroxyl protecting group.

Hydroxyl protecting groups are defined herein, and include, but are not limited to, —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA, —Si(RA)3, C1-10 alkyl, C1-10 fluoroalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 RD groups, wherein RA, RB, and RD are as defined herein.
In certain embodiments, R17 is hydrogen, —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA, or —Si(RA)3, wherein RA and RB are as defined herein. In certain embodiments, R17 is hydrogen or —C(═O)RA, wherein RA is as defined herein. In certain embodiments, R17 is hydrogen or —C(═O)RA, wherein RA is C1-10 alkyl. In certain embodiments, R17 is hydrogen or —C(═O)RA, wherein RA is C1-6 alkyl. In certain embodiments, R17 is hydrogen or —C(═O)CH3. In certain embodiments, R17 is hydrogen. In certain embodiments, R17 is —C(═O)CH3.
In certain embodiments, Ra, Rb, R1, R2, R6, R7, R8, and R17 are each hydrogen, and R3 and R4 are each —C(═O)CH3.
In certain embodiments, Ra, Rb, R1, R2, R6, R7, R8, and R17 are each hydrogen, R3 and R4 are each —C(═O)CH3, and R12 is the group (D) wherein R13, R14, R15, and R16 are each hydrogen.
Various sub-genera of Formula (III) are further described below and herein. For example, in certain embodiments, the compound of Formula (III) is of Formula (III-a):




or a pharmaceutically acceptable form thereof; wherein R12 and G are as defined herein.

In yet other embodiments, the compound of the Formula (III) is of Formula (III-b):




or a pharmaceutically acceptable form thereof; wherein G is as defined herein.

Compounds of Formula (IV)

The present invention further provides compounds of Formula (IV), as provided below, which include compounds comprising Rings E and F, and optionally Ring D, of the moenomycin A sugar scaffold.
For example, in one aspect, provided is a compound of Formula (IV):




or a pharmaceutically acceptable form thereof; wherein R1, R2, R3, R6, R7, R12, Ra, and Rb are as defined above and herein; G is a group of Formula (a), (b), or (c) as defined above and herein; and R18 is hydrogen or a hydroxyl protecting group.

Hydroxyl protecting groups are defined herein, and include, but are not limited to, —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA, —Si(RA)3, C1-10 alkyl, C1-10 fluoroalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 RD groups, wherein RA, RB, and RD are as defined herein.
In certain embodiments, R18 is hydrogen, —C(═O)RA, —CO2RA, —C(═O)—O—C(═O)RA, —C(═O)SRA, —C(═O)N(RB)2, —C(═O)NRBSO2RA, —C(═NRB)RA, —C(═NRB)ORA, —C(═NRB)N(RB)2, —C(═S)RA, —C(═S)N(RA)2, —C(═S)SRA, —SO2RA, —SO2ORA, —SO2N(RB)2, —S(═O)RA, and —Si(RA)3, wherein RA and RB are as defined herein. In certain embodiments, R18 is hydrogen or —C(═O)RA, wherein RA is as defined herein. In certain embodiments, R18 is hydrogen or —C(═O)RA, wherein RA is C1-10 alkyl. In certain embodiments, R18 is hydrogen or —C(═O)RA, wherein RA is C1-6 alkyl. In certain embodiments, R18 is hydrogen or —C(═O)CH3. In certain embodiments, R18 is hydrogen. In certain embodiments, R18 is —C(═O)CH3.
In certain embodiments Ra, Rb, R1, R2, R6, R7, and R18 are each hydrogen, and R3 is —C(═O)CH3.
In certain embodiments Ra, Rb, R1, R2, R6, R7, and R18 are each hydrogen, R3 is —C(═O)CH3, and R12 is the group (D) wherein R13, R14, R15, and R16 are each hydrogen.
Various sub-genera of Formula (IV) are further described herein.
For example, in certain embodiments, the compound of Formula (IV) is a compound of Formula (IV-a):




or a pharmaceutically acceptable form thereof; wherein R12 and G are as defined herein.

In yet other embodiments the compound of Formula (IV) is of Formula (IV-b):




or a pharmaceutically acceptable form thereof; wherein G is as defined herein.

Group G of Formula (a)

As generally described herein, in certain embodiments, compounds of Formula (I), (II), (III), and (IV) include a group G of Formula (a):




wherein a is 3, 4, or 5.

For example, in certain embodiments, the group G a group selected from the group consisting of:




wherein a is 3;





wherein a is 4; or





wherein a is 5.

Group G of Formula (b)

As generally described herein, in certain embodiments, compounds of Formula (I), (II), (III), and (IV) include a group G of Formula (b):




wherein:

    
    
        X1, X2, X3, X4, X5, X6, and X7 are each independently hydrogen or halogen;
        d is an integer between 1 and 25, inclusive; and
        e is an integer of between 2 and 25, inclusive;
        provided the sum of d and e is greater than 16.
    
    


In certain embodiments, e is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 24, or 25. In certain embodiments, d is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 24, or 25. Any particular combination of e or d is contemplated, provided the sum of d and e is greater than 16.
For example, in certain embodiments, e is 16 or an integer greater than 16, and d is 1 or an integer greater than 1. In certain embodiments, e is 15, and d is 2 or an integer greater than 2. In certain embodiments, e is 14, and d is 3 or an integer greater than 3. In certain embodiments, e is 13, and d is 4 or an integer greater than 4. In certain embodiments, e is 12, and d is 5 or an integer greater than 5. In certain embodiments, e is 11, and d is 6 or an integer greater than 6. In certain embodiments, e is 10, and d is 7 or an integer greater than 7. In certain embodiments, e is 9, and d is 8 or an integer greater than 8. In certain embodiments, e is 8, and d is 9 or an integer greater than 9. In certain embodiments, e is 7, and d is 10 or an integer greater than 10. In certain embodiments, e is 6, and d is 11 or an integer greater than 11. In certain embodiments, e is 5, and d is 12 or an integer greater than 12. In certain embodiments, e is 4, and d is 13 or an integer greater than 13. In certain embodiments, e is 3, and d is 14 or an integer greater than 14. In certain embodiments, e is 2, and d is 15 or an integer greater than 15.
In certain embodiments, e is 10, and d is 7 or an integer greater than 7, e.g., d is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 24, or 25. In certain embodiments, e is 10 and d is 7. In certain embodiments, e is 10 and d is 8. In certain embodiments, e is 10 and d is 9. In certain embodiments, e is 10 and d is 10. In certain embodiments, e is 10 and d is 11. In certain embodiments, e is 10 and d is 12. In certain embodiments, e is 10 and d is 13. In certain embodiments, e is 10 and d is 14. In certain embodiments, e is 10 and d is 15.
In certain embodiments, at least one of X1, X2, X3, X4, X5, X6, or X7 is halogen, e.g., fluoro. In certain embodiments, at least two of X1, X2, X3, X4, X5, X6, or X7 is halogen. In certain embodiments, at least three of X1, X2, X3, X4, X5, X6, or X7 is halogen. In certain embodiments, at least four of X1, X2, X3, X4, X5, X6, or X7 is halogen. In certain embodiments, at least five of X1, X2, X3, X4, X5, X6, or X7 is halogen. In certain embodiments, at least six of X1, X2, X3, X4, X5, X6, or X7 is halogen.
In certain embodiments, each instance of X1 and X2 is hydrogen. In certain embodiments, each instance of X1 and X2 is halogen, e.g., fluoro.
In certain embodiments, each instance of X3 and X4 is hydrogen. In certain embodiments, each instance of X3 and X4 is halogen, e.g., fluoro.
In certain embodiments, each instance of X5, X6, and X7 is hydrogen. In certain embodiments, each instance of X5, X6, and X7 is halogen, e.g., fluoro.
In certain embodiments, each instance of X1 and X2 is fluoro, optionally wherein each instance of X3 and X4 is fluoro and/or each instance of X5, X6, and X7 is fluoro. In certain embodiments, X1 and X2 are each fluoro, X3 and X4 are each hydrogen, and X5, X6, and X7 are each hydrogen. In certain embodiments, X1 and X2 are each fluoro, X3 and X4 are each fluoro, and X5, X6, and X7 are each hydrogen. In certain embodiments, X1 and X2 are each fluoro, X3 and X4 are each hydrogen, and X5, X6, and X7 are each fluoro. In certain embodiments, X1 and X2 are each fluoro, X3 and X4 are each fluoro, and X5, X6, and X7 are each fluoro.
Alternatively, in certain embodiments, each instance of X3 and X4 is fluoro, optionally wherein each instance of X1 and X2 is fluoro and/or each instance of X5, X6, and X7 is fluoro. In certain embodiments, X3 and X4 are each fluoro, X1 and X2 are each hydrogen, and X5, X6, and X7 are each hydrogen. In certain embodiments, X3 and X4 are each fluoro, X1 and X2 are each hydrogen, and X5, X6, and X7 are each fluoro. In certain embodiments, X3 and X4 are each fluoro, X1 and X2 are each fluoro, and X5, X6, and X7 are each hydrogen. In certain embodiments, X3 and X4 are each fluoro, X1 and X2 are each fluoro, and X5, X6, and X7 are each fluoro.
Exemplary fluoroalkyl groups of formula (b), wherein X1 and X2 are hydrogen and X3, X4, X5, X6, and X7 are each fluoro include, but are not limited to:




wherein e is 10, and d is 7;





wherein e is 10, and d is 8;





wherein e is 10, and d is 9;





wherein e is 10, and d is 10;





wherein e is 10, and d is 11;





wherein e is 10, and d is 12;





wherein e is 10, and d is 13;





wherein e is 10, and d is 14; and





wherein e is 10, and d is 15.

Exemplary fluoroalkyl groups of formula (b), wherein each instance of X1, X2, X3, X4, X5, X6, and X7 is fluoro, include but are not limited to:




wherein e is 10, and d is 7;





wherein e is 10, and d is 8;





wherein e is 10, and d is 9;





wherein e is 10, and d is 10;





wherein e is 10, and d is 11;





wherein e is 10, and d is 12;





wherein e is 10, and d is 13;





wherein e is 10, and d is 14; and





wherein e is 10, and d is 15.

Group G of Formula (c)

As generally described herein, in certain embodiments, compounds of Formula (I), (II), (III), and (IV) include a group G of Formula (c):




wherein:

    
    
        Y is —O—, —S—, —NRY—, or an optionally substituted methylene group, wherein RY is hydrogen, optionally substituted aliphatic, or an amino protecting group;
        each instance of Rc is independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORe, —SRe, —NHRe, and —N(Re)2, wherein each instance of Re is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two Re groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;
        each instance of Rd is independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORf, —SRf, —NHRf, or —N(Rf)2, wherein each instance of Rf is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two Rf groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;
        Rz is hydrogen, —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORg, —SRg, —NHRg, or —N(Rg)2, wherein each instance of Rg is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl or two Rg groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;
        each instance of n is, independently, 0, 1, 2, 3, or 4;
        each instance of m is, independently, 0, 1, 2, 3, or 4; and
        x is 1, 2, 3, 4, 5, or 6.
    
    


As generally defined above, Y is —O—, —S—, —NRY—, or an optionally substituted methylene group, wherein RY is hydrogen, optionally substituted aliphatic, or an amino protecting group. In certain embodiments, Y is —O—. In certain embodiments, Y is —S—. In certain embodiments, Y is —NRY—. In certain embodiments, Y is an optionally substituted methylene group, e.g., —CH2—.
As generally defined above, each instance of Rc is independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORe, —SRe, —NHRe, or —N(Re)2, wherein each instance of Re is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two Re groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring; and n is 0, 1, 2, 3, or 4.
In certain embodiments, each instance of Rc is independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORe, —SRe, —NHRe, or —N(Re)2, wherein each instance of Re is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two Re groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring; wherein each instance of aliphatic, heteroaliphatic, carbocycyl, heterocycyl, aryl and heteroaryl is independently unsubstituted or substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substituents, as defined herein. In certain embodiments, each instance of aliphatic, heteroaliphatic, carbocycyl, heterocycyl, aryl and heteroaryl is independently unsubstituted or substituted with C1-6alkyl, C1-6fluoroalkyl or halogen.
In certain embodiments, each instance of Rc is independently —F, aliphatic, heteroaliphatic, carbocycyl, heterocycyl, aryl, or heteroaryl, wherein each instance of aliphatic, heteroaliphatic, carbocycyl, heterocycyl, aryl and heteroaryl is independently unsubstituted or substituted with C1-6alkyl, C1-6fluoroalkyl or halogen.
In certain embodiments, each instance of Rc is independently —F or alkyl, wherein each instance of alkyl is independently unsubstituted or substituted with C1-6alkyl, C1-6fluoroalkyl or halogen.
In certain embodiments, n is 0 or 1. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2.
As generally defined above, each instance of Rd is independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORf, —SRf, —NHRf, or —N(Rf)2, wherein each instance of Rf is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two Rf groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring; and m is 0, 1, 2, 3, or 4.
In certain embodiments, each instance of Rd is independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORf, —SRf, —NHRf, or —N(Rf)2, wherein each instance of Rf is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two Rf groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring; wherein each instance of aliphatic, heteroaliphatic, carbocycyl, heterocycyl, aryl and heteroaryl is independently unsubstituted or substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substituents, as defined herein. In certain embodiments, each instance of aliphatic, heteroaliphatic, carbocycyl, heterocycyl, aryl and heteroaryl is independently unsubstituted or substituted with C1-6alkyl, C1-6fluoroalkyl or halogen.
In certain embodiments, each instance of Rd is independently —F, aliphatic, heteroaliphatic, carbocycyl, heterocycyl, aryl, or heteroaryl, wherein each instance of aliphatic, heteroaliphatic, carbocycyl, heterocycyl, aryl, and heteroaryl is independently unsubstituted or substituted with C1-6alkyl, C1-6fluoroalkyl or halogen.
In certain embodiments, each instance of Rd is independently —F or alkyl, wherein each instance of alkyl is independently unsubstituted or substituted with C1-6alkyl, C1-6fluoroalkyl, or halogen.
In certain embodiments, m is 0 or 1. In certain embodiments, m is 0. In certain embodiments, m is 1. In certain embodiments, m is 2.
In certain embodiments, Rz is an ortho, meta, or para substituent to the —OCH2-linking group. In certain embodiments, Rz is a meta substituent.
As generally defined above, Rz is hydrogen, —F, —Br, —I, —Cl, optionally substituted aliphatic, heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORg, —SRg, —NHRg, or —N(Rg)2, wherein each instance of Rg is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl or two Rg groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring.
In certain embodiments, Rz is hydrogen, —F, —Br, —I, —Cl, optionally substituted aliphatic, heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORg, —SRg, —NHRg, or —N(Rg)2, wherein each instance of Rg is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl or two Rg groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring, wherein each instance of aliphatic, heteroaliphatic, carbocycyl, heterocycyl, aryl and heteroaryl is independently unsubstituted or substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substituents, as defined herein. In certain embodiments, each instance of aliphatic, heteroaliphatic, carbocycyl, heterocycyl, aryl and heteroaryl is independently unsubstituted or substituted with C1-6alkyl, C1-6fluoroalkyl or halogen.
In certain embodiments, Rz is hydrogen, alkyl, alkenyl, alkynyl, carbocycyl, heterocycyl, aryl, heteroaryl, —ORg, —SRg, —NHRg, or —N(Rg)2, wherein each instance of Rg is independently hydrogen, alkyl, alkenyl, alkynyl, carbocycyl, heterocycyl, aryl, heteroaryl, or two Rg groups are joined to form a 5- to 6-membered heterocycyl or heteroaryl ring, and wherein each instance of alkyl, alkenyl, alkynyl, carbocycyl, heterocycyl, aryl, and heteroaryl, is independently unsubstituted or substituted with C1-6alkyl, C1-6fluoroalkyl or halogen.
In certain embodiments, Rz is hydrogen or aryl, wherein aryl is unsubstituted or substituted with C1-6alkyl, C1-6fluoroalkyl or halogen.
As generally depicted above, x is 1, 2, 3, 4, 5, or 6. In certain embodiments, x is 1 or 2. In certain embodiments, x is 1. In certain embodiments, x is 2.
It is understood that each repeat unit of formula (c), when x is greater than 1, can optionally differ from one another, arising from differences in the independent variables Y, Rc, Rd, n and m, as well as different substitution patterns on and between each repeating unit. Thus, in further defining the compounds of the present invention, it is also generally helpful to further designate Y, Rc, Rd, n and m, with a sequential number corresponding to the first, second, third, fourth, fifth or sixth sequential group from which it is formally a member, e.g., Y, Rc, Rd, n, m and x can also be referred to as Y1Rc1, Rd1, n1 and m1 for the first group in the sequence; Y2, Rc2, Rd2, n2 and m2 for the second optional repeating unit in the sequence; Y3, Rc3, Rd3, n3 and m3 for the third optional repeating unit in the sequence; Y4, Rc4, Rd4, n4 and m4 for the fourth optional repeating unit in the sequence; Y5, Rc5, Rd5, n5 and m5 for the fifth optional repeating unit in the sequence; and Y6, Rc6, Rd6, n6 and m6 for the sixth optional repeating unit in the sequence.
For example, in certain embodiments, the group of Formula (c) is of the formula:




wherein x is 1;





wherein x is 2;





wherein x is 3;





wherein x is 4;





wherein x is 5; or





wherein x is 6;

wherein:

Rc1, Rc2, Rc3, Rc4, Rc5, and Rc6 each independently correspond to the definition and various embodiments of Rc;
Rd1, Rd2, Rd3, Rd4, Rd5, and Rd6 each independently correspond to the definition and various embodiments of Rd;
n1, n2, n3, n4, n5, and n6 each independently correspond to the definition and various embodiments of n;
m1, m2, m3, m4, m5, and m6 each independently correspond to the definition and various embodiments of m;
Y1, Y2, Y3, Y4, Y5, and Y6, each independently correspond to the definition and various embodiments of Y; and
Rz is as defined herein.
In certain embodiments, the group of Formula (c) is of the formula:




wherein Y, Rz, Rc, Rd, m, n, and x are as defined herein.

In certain embodiments, the group of Formula (c) is:




wherein x is 1;





wherein x is 2;





wherein x is 3:





wherein x is 4;





wherein x is 5; or





wherein x is 6;

wherein:

Rc1, Rc2, Rc3, Rc4, Rc5, and Rc6 each independently correspond to the definition and various embodiments of Rc;
Rd1, Rd2, Rd3, Rd4, Rd5, and Rd6 each independently correspond to the definition and various embodiments of Rd;
n1, n2, n3, n4, n5, and n6 each independently correspond to the definition and various embodiments of n;
m1, m2, m3, m4, m5, and m6 each independently correspond to the definition and various embodiments of m;
Y1, Y2, Y3, Y4, Y5, and Y6, each independently correspond to the definition and various embodiments of Y;
and Rz is as defined herein.
In certain embodiments, each of n, n1, n2, n3, n4, n5, and n6 is 0.
In certain embodiments, each of m, m1, m2, m3, m4, m5, and m6 is 0.
In certain embodiments, each of Y, Y1, Y2, Y3, Y4, Y5, and Y6 and —O—.
Specifically Contemplated Embodiments
Compounds of the present invention specifically contemplated include, but are not limited to, compounds having the following structure:




or a pharmaceutically acceptable form thereof;

wherein G is selected from the group consisting of




Pharmaceutical Compositions

The present invention also provides pharmaceutical compositions comprising an effective amount of a compound of Formula (I), (II), (III), or (IV), or a pharmaceutically acceptable form thereof, and, optionally, a pharmaceutically acceptable excipient.
Pharmaceutically acceptable excipients include any and all solvents, diluents or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. General considerations in formulation and/or manufacture of pharmaceutical compositions agents can be found, for example, in Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), and Remington: The Science and Practice of Pharmacy, 21st Edition (Lippincott Williams & Wilkins, 2005).
Pharmaceutical compositions described herein can be prepared by any method known in the art of pharmacology. In general, such preparatory methods include the steps of bringing the compound of the present invention (the “active ingredient”) into association with a carrier and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping and/or packaging the product into a desired single- or multi-dose unit.
Pharmaceutical compositions can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses. As used herein, a “unit dose” is discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.
Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition of the invention will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100% (w/w) active ingredient.
Pharmaceutically acceptable excipients used in the manufacture of provided pharmaceutical compositions include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents may also be present in the composition.
Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc., and combinations thereof.
Exemplary granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, etc., and combinations thereof.
Exemplary surface active agents and/or emulsifiers include natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite (aluminum silicate) and Veegum (magnesium aluminum silicate)), long chain amino acid derivatives, high molecular weight alcohols (e.g. stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g. polyoxyethylene sorbitan monolaurate (Tween 20), polyoxyethylene sorbitan (Tween 60), polyoxyethylene sorbitan monooleate (Tween 80), sorbitan monopalmitate (Span 40), sorbitan monostearate (Span 60), sorbitan tristearate (Span 65), glyceryl monooleate, sorbitan monooleate (Span 80)), polyoxyethylene esters (e.g. polyoxyethylene monostearate (Myrj 45), polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g. Cremophor), polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether (Brij 30)), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F-68, Poloxamer P188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and/or combinations thereof.
Exemplary binding agents include starch (e.g. cornstarch and starch paste), gelatin, sugars (e.g. sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g. acacia, sodium alginate, extract of fish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, etc., and/or combinations thereof.
Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
Exemplary antioxidants include alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like), citric acid and salts and hydrates thereof (e.g., citric acid monohydrate), fumaric acid and salts and hydrates thereof, malic acid and salts and hydrates thereof, phosphoric acid and salts and hydrates thereof, and tartaric acid and salts and hydrates thereof. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
Exemplary antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
Other preservatives include tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus, Phenonip, methylparaben, Germall 115, Germaben II, Neolone, Kathon, and Euxyl. In certain embodiments, the preservative is an antioxidant. In other embodiments, the preservative is a chelating agent.
Exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, etc., and combinations thereof.
Exemplary lubricating agents include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, etc., and combinations thereof.
Exemplary natural oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils. Exemplary synthetic oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and combinations thereof.
Liquid dosage forms for oral and parenteral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredients, the liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. In certain embodiments for parenteral administration, the conjugates of the invention are mixed with solubilizing agents such as Cremophor, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and combinations thereof.
Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
Compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing the conjugates of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl-pyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may comprise buffering agents.
Solid compositions of a similar type can be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. Solid compositions of a similar type can be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
The active ingredients can be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active ingredient can be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may comprise buffering agents. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
Dosage forms for topical and/or transdermal administration of a compound of this invention may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants and/or patches. Generally, the active ingredient is admixed under sterile conditions with a pharmaceutically acceptable carrier and/or any needed preservatives and/or buffers as can be required. Additionally, the present invention contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of an active ingredient to the body. Such dosage forms can be prepared, for example, by dissolving and/or dispensing the active ingredient in the proper medium. Alternatively or additionally, the rate can be controlled by either providing a rate controlling membrane and/or by dispersing the active ingredient in a polymer matrix and/or gel.
Suitable devices for use in delivering intradermal pharmaceutical compositions described herein include short needle devices such as those described in U.S. Pat. Nos. 4,886,499; 5,190,521; 5,328,483; 5,527,288; 4,270,537; 5,015,235; 5,141,496; and 5,417,662. Intradermal compositions can be administered by devices which limit the effective penetration length of a needle into the skin, such as those described in PCT publication WO 99/34850 and functional equivalents thereof. Jet injection devices which deliver liquid vaccines to the dermis via a liquid jet injector and/or via a needle which pierces the stratum corneum and produces a jet which reaches the dermis are suitable. Jet injection devices are described, for example, in U.S. Pat. Nos. 5,480,381; 5,599,302; 5,334,144; 5,993,412; 5,649,912; 5,569,189; 5,704,911; 5,383,851; 5,893,397; 5,466,220; 5,339,163; 5,312,335; 5,503,627; 5,064,413; 5,520,639; 4,596,556; 4,790,824; 4,941,880; 4,940,460; and PCT publications WO 97/37705 and WO 97/13537. Ballistic powder/particle delivery devices which use compressed gas to accelerate vaccine in powder form through the outer layers of the skin to the dermis are suitable. Alternatively or additionally, conventional syringes can be used in the classical mantoux method of intradermal administration.
Formulations suitable for topical administration include, but are not limited to, liquid and/or semi liquid preparations such as liniments, lotions, oil in water and/or water in oil emulsions such as creams, ointments and/or pastes, and/or solutions and/or suspensions. Topically-administrable formulations may, for example, comprise from about 1% to about 10% (w/w) active ingredient, although the concentration of the active ingredient can be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further comprise one or more of the additional ingredients described herein.
A pharmaceutical composition of the invention can be prepared, packaged, and/or sold in a formulation suitable for pulmonary administration via the buccal cavity. Such a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers or from about 1 to about 6 nanometers. Such compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant can be directed to disperse the powder and/or using a self propelling solvent/powder dispensing container such as a device comprising the active ingredient dissolved and/or suspended in a low-boiling propellant in a sealed container. Such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. Alternatively, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers. Dry powder compositions may include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.
Low boiling propellants generally include liquid propellants having a boiling point of below 65° F. at atmospheric pressure. Generally the propellant may constitute 50 to 99.9% (w/w) of the composition, and the active ingredient may constitute 0.1 to 20% (w/w) of the composition. The propellant may further comprise additional ingredients such as a liquid non-ionic and/or solid anionic surfactant and/or a solid diluent (which may have a particle size of the same order as particles comprising the active ingredient).
Pharmaceutical compositions of the invention formulated for pulmonary delivery may provide the active ingredient in the form of droplets of a solution and/or suspension. Such formulations can be prepared, packaged, and/or sold as aqueous and/or dilute alcoholic solutions and/or suspensions, optionally sterile, comprising the active ingredient, and may conveniently be administered using any nebulization and/or atomization device. Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, and/or a preservative such as methylhydroxybenzoate. The droplets provided by this route of administration may have an average diameter in the range from about 0.1 to about 200 nanometers.
Formulations described herein as being useful for pulmonary delivery are useful for intranasal delivery of a pharmaceutical composition of the invention. Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 to 500 micrometers. Such a formulation is administered by rapid inhalation through the nasal passage from a container of the powder held close to the nares.
Formulations for nasal administration may, for example, comprise from about as little as 0.1% (w/w) and as much as 100% (w/w) of the active ingredient, and may comprise one or more of the additional ingredients described herein. A pharmaceutical composition of the invention can be prepared, packaged, and/or sold in a formulation for buccal administration. Such formulations may, for example, be in the form of tablets and/or lozenges made using conventional methods, and may contain, for example, 0.1 to 20% (w/w) active ingredient, the balance comprising an orally dissolvable and/or degradable composition and, optionally, one or more of the additional ingredients described herein. Alternately, formulations for buccal administration may comprise a powder and/or an aerosolized and/or atomized solution and/or suspension comprising the active ingredient. Such powdered, aerosolized, and/or aerosolized formulations, when dispersed, may have an average particle and/or droplet size in the range from about 0.1 to about 200 nanometers, and may further comprise one or more of the additional ingredients described herein.
A pharmaceutical composition of the invention can be prepared, packaged, and/or sold in a formulation for ophthalmic administration. Such formulations may, for example, be in the form of eye drops including, for example, a 0.1/1.0% (w/w) solution and/or suspension of the active ingredient in an aqueous or oily liquid carrier. Such drops may further comprise buffering agents, salts, and/or one or more other of the additional ingredients described herein. Other opthalmically-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form and/or in a liposomal preparation. Ear drops and/or eye drops are contemplated as being within the scope of this invention.
Although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with ordinary experimentation.
Still further encompassed by the invention are kits (e.g., pharmaceutical packs). The kits provided may comprise an inventive pharmaceutical composition or compound and a container (e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container). In some embodiments, provided kits may optionally further include a second container comprising a pharmaceutical excipient for dilution or suspension of an inventive pharmaceutical composition or compound. In some embodiments, the inventive pharmaceutical composition or compound provided in the container and the second container are combined to form one unit dosage form.
Optionally, a single container may comprise one or more compartments for containing an inventive pharmaceutical composition or compound, and/or a pharmaceutically acceptable excipient for suspension or dilution. In some embodiments, a single container can be appropriate for modification such that the container may receive a physical modification so as to allow combination of compartments and/or components of individual compartments. For example, a foil or plastic bag may comprise two or more compartments separated by a perforated seal which can be broken so as to allow combination of contents of two individual compartments once the signal to break the seal is generated. A kit may thus comprise such multi-compartment containers providing an inventive pharmaceutical composition or compound and one or more pharmaceutically acceptable excipients.
Optionally, instructions for use are additionally provided in such kits of the invention. Such instructions may provide, generally, for example, instructions for dosage and administration. In other embodiments, instructions may further provide additional detail relating to specialized instructions for particular containers and/or systems for administration. Still further, instructions may provide specialized instructions for use in conjunction and/or in combination with an additional therapeutic agent.
Methods of Use and Treatment
The present invention also provides methods of treating or preventing an infection comprising administering to a subject an effective amount a compound of Formula (I), (II), (III), or (IV), or a pharmaceutically acceptable form thereof. In certain embodiments, the infection is a bacterial infection. In certain embodiments, the bacterial infection is caused by a Gram-positive bacterium. In certain embodiments, the bacterial infection is caused by a Gram-negative bacterium.
The present invention also provides methods of inhibiting microbial growth, e.g., bacterial, viral, parasitic, or fungal growth, comprising contacting a microbial organism, e.g., a bacterium, a virus, a parasite, or a fungus, with an effective amount of a compound of Formula (I), (II), (III), or (IV), or a pharmaceutically acceptable form thereof. In certain embodiments, the method is an in vitro or in situ method. In certain embodiments, the microbial organism is a bacterium. In certain embodiments, the bacterium is a Gram-positive bacterium. In certain embodiments, the bacterium is a Gram-negative bacterium.
In certain embodiments, the bacterial infection being treated or prevented is caused by Gram-negative bacteria. Exemplary Gram-negative bacteria include, but are not limited to, Escherichia coli, Salmonella (e.g., Salmonella enteritidis, and Salmonella typhi), Hemophilus influenzae, Klebsiella pneumoniae, Legionella pneumophila, Pseudomonas aeruginosa, Proteus mirabilis, Enterobacter cloacae, Serratia marcescens, Helicobacter pylori, Pseudomonas, Moraxella (e.g., Moraxella catarrhalis), Helicobacter, Stenotrophomonas, Bdellovibrio, acetic acid bacteria, Legionella, and Neisseria (e.g., Neisseria gonorrhoeae, Neisseria meningitidis).
In certain embodiments, the infection being treated or prevented is caused by Gram-positive bacteria. Exemplary Gram-positive bacteria include, but are not limited to, Streptococci bacteria such as Streptococcus Group A, Streptococcus Group B, Streptococcus Group G (e.g., Streptococcus anginosus, Streptococcus pneumoniae), Streptococcus viridans, Streptococcus pyogenes (e.g., ATCC8668); Staphylococci bacteria such as Staphylococcus aureaus (e.g., Staphylococcus aureus (e.g., ATCC29213), Staphylococcus aureus (e.g., ATCC43300) MSA), and Staphylococcus saprophyticus; Micrococcus bacteria such as Micrococcus luteus (e.g., ATCC272); and Enterococcus bacteria such as Enterococcus faecalis (e.g., ATCC29212) and Enterococcus faecalis (e.g., ATCC51299).
In certain embodiments, the bacterial infection being treated or prevented is caused by vancomycin-resistant bacteria. In certain embodiments, the bacterial infection is caused by vancomycin-resistant Gram-negative or Gram-positive bacteria. In certain embodiments, the bacterial infection is caused by vancomycin-resistant Gram-positive bacteria. In certain embodiments, the bacterial infection is caused by vancomycin-resistant Staphylococcus aureus. In certain embodiments, the bacterial infection is caused by vancomycin-resistant Gram-positive enterococci (VRE). In certain embodiments, the bacterial infection is caused by methicillin-resistant bacteria. In certain embodiments, the bacterial infection is caused by methicillin-resistant Staphylococcus aureus (MRSA).
The compounds and pharmaceutical compositions described herein may be used to treat any infection including, but not limited to, anthrax, bacterial meningitis, botulism, brucellosis, campylobacteriosis, cholera, diphtheria, gonorrhea, impetigo, legionellosis, leprosy (Hansen's disease), leptospirosis, listeriosis, lyme disease, melioidosis, MRSA infection, nocardiosis, pertussis (whooping cough), plague, pneumococcal pneumonia, psittacosis, Q fever, rocky mountain spotted fever (RMSF), scarlet fever, shigellosis, syphilis, tetanus, trachoma, tuberculosis, tularemia, typhoid fever, typhus, urinary tract infection (UTI), skin infections, gastrointestinal infections, genito-urinary infections, and systemic infections.
Particularly useful compounds of the present invention include those with biological activity. In certain embodiments, the compounds of the invention exhibit antibacterial activity. For example, the compound may have a mean inhibitory concentration, with respect to a particular bacteria, of less than 50 μg/mL, less than 25 μg/mL, less than 5 μg/mL, or less than 1 μg/mL.
A method for treating an infection is provided comprising administering an effective amount of an inventive compound, or a pharmaceutical composition thereof, to a subject in need thereof, in such amounts and for such time as is necessary to achieve the desired result.
The compounds and compositions for use in methods of the present invention may be administered in such amounts, time, and route deemed necessary in order to achieve the desired result. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular compound, its mode of administration, its mode of activity, and the like. The compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
In some embodiments, an effective amount of an inventive compound is delivered to the subject prior to, simultaneously with, and/or after diagnosis of an infection. In some embodiments, a therapeutic amount of an inventive composition is delivered to the subject prior to, simultaneously with, and/or after onset of symptoms associated with an infection. In some embodiments, the amount of inventive compound is sufficient to treat, alleviate, ameliorate, relieve, delay onset of, inhibit progression of, reduce severity of, and/or reduce incidence of one or more symptoms or features associated with the infection.
The inventive compounds and compositions of the present invention may be administered by any route. In some embodiments, the inventive compounds and compositions are administered via a variety of routes, including oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, bucal, enteral, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol. Specifically contemplated routes are systemic intravenous injection, regional administration via blood and/or lymph supply, and/or direct administration to an affected site. In general the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g., its stability in the environment of the gastrointestinal tract), the condition of the subject (e.g., whether the subject is able to tolerate oral administration), etc. At present the oral and/or nasal spray and/or aerosol route is most commonly used to deliver therapeutic agents directly to the lungs and/or respiratory system. However, the invention encompasses the delivery of the inventive pharmaceutical composition by any appropriate route taking into consideration likely advances in the sciences of drug delivery.
The exact amount of a compound required to achieve an effective amount at a desired site in the subject will vary from subject to subject, depending on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound(s), mode of administration, and the like. In certain embodiments of the present invention, an effective amount of an inventive compound for administration one or more times a day to a 70 kg adult human may comprise about 0.001 mg/kg to about 100 mg/kg of an inventive compound per unit dosage form. It will be appreciated that dose ranges as described herein provide guidance for the administration of inventive pharmaceutical compositions to an adult. The amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.
In certain embodiments, the compounds of the invention may be administered at dosage levels sufficient to deliver from about 0.001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, from about 0.1 mg/kg to about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, and from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect. The desired dosage may be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In certain embodiments, the desired dosage may be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).
It will be also appreciated that an inventive compound or composition thereof, as described above and herein, can be administered in combination with one or more additional therapeutically active agents (“agent”). By “in combination with,” it is not intended to imply that the compound and agent must be administered at the same time and/or formulated for delivery together, although these methods of delivery are within the scope of the invention. The inventive compound can be administered concurrently with, prior to, or subsequent to, the administration an agent. In general, each compound or agent used in combination will be administered at a dose and/or on a time schedule determined for that compound or agent.
In will further be appreciated that the additional therapeutically active agent utilized in this combination may be administered together in a single composition or administered separately in different compositions.
In general, it is expected that additional therapeutically active agents utilized in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.
The particular combination to employ in a regimen will take into account compatibility of the inventive compound with the additional therapeutically active agent and/or the desired therapeutic effect to be achieved.
It will also be appreciated that the therapy employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered in combination with another antibacterial agent), and/or they may achieve different effects (e.g., control of any adverse effects). For example, an agent may improve the bioavailability, reduce and/or modify the metabolism, inhibit the excretion, and/or modify the distribution of the inventive compound within the body of the subject.
Therapeutically active agents include, but are not limited to, organic molecules that are drug compounds, peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, and vitamins. Therapeutically active agents include any substance used as a medicine for treatment, prevention, delay, reduction or amelioration of a disease, condition, or disorder, and refers to a substance that is useful for therapy, including prophylactic and therapeutic treatment. A therapeutically active agent also includes a compound that increases the effect or effectiveness of another compound, for example, by enhancing potency or reducing adverse effects of the other compound.
For example, in certain embodiments, an additional therapeutically active agent is another antibacterial agent. Exemplary antibacterial agents include, but are not limited to, aminoglycosides, glycoproteins (e.g. vancomycin, teicoplanin), penicillins, cephalosporins, carbapenems (e.g., imipenem, cilastin, ertapenem), chloramphenicol, macrolides (e.g., erythromycin), lincosamides (e.g., lincomycin, clindamycin), fusidic acid, tetracyclines, streptogramins, quinolones (e.g., fluoroquinolones, ciprofloxacin, levofloxacin), rifampicin, nitrofurans, polymyxins, daptomycin, sulphonamides, diaminopyrimidines etc.
Methods of Synthesis
As generally described above, the present invention provides compounds of Formula (I), (II), (III), and (IV), wherein the sugar portion comprising Rings E and F, and optionally Rings A, B, C, and D, is derived from moenomycin A. Thus, in certain embodiments, the present invention provides methods of synthesis of these compounds from the natural product moenomycin A. The methods described herein include the use of synthetic methods (i.e., building up, adding groups) as well as degradative methods (i.e., breaking down, removing groups) to arrive at compounds of the present invention. For example, Rings A, B, C and/or D of moenomycin A may optionally be cleaved using one or more degradative steps. The degraded compound may then be further synthetically modified (e.g., using a combination of degradative and synthetic steps) to provide a compound of Formula (I), (II), (III), or (IV).
In one aspect, the present invention provides a method of synthesizing a compound of Formula (II) comprising the steps of:

    
    
        (i) providing moenomycin A;
        (ii) removing the phosphoglycerate linker and moenocinol chain of moenomycin A, and optionally Rings A and/or D, to provide a saccharide group of Formula (II-S1):
    
    






wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12 are as defined herein;

    
    
        (iii) reacting (II-S1) with a phosphitylation agent to provide a H-phosphonate diester of Formula (II-S2):
    
    






wherein Ra is as defined herein; and

    
    
        (iv) coupling (II-S2) with a compound of Formula (P1):
    
    






wherein Rb and G are as defined herein, to provide a compound of Formula (II) or a pharmaceutically acceptable form thereof.

In another aspect, the present invention provides a method of synthesizing a compound of Formula (III) comprising the steps of:

    
    
        (i) providing moenomycin A;
        (ii) removing the phosphoglycerate linker, moenocinol chain, and Rings A and B of moenomycin A, and optionally Ring D, to provide a saccharide group of Formula (III-S1):
    
    






wherein R1, R2, R3, R4, R6, R7, R8, R17, and R12 are as defined herein;

    
    
        (iii) reacting (III-S1) with a phosphitylation agent to provide a H-phosphonate diester of the formula (III-S2):
    
    






wherein Ra is as defined herein; and

    
    
        (iv) coupling (III-S2) with a compound of Formula (P1):
    
    






wherein Rb and G are as defined herein, to provide a compound of Formula (III), or a pharmaceutically acceptable form thereof.

In yet another aspect, the present invention provides a method of synthesizing a compound of Formula (IV) comprising the steps of:

    
    
        (i) providing moenomycin A;
        (ii) removing the phosphoglycerate linker, moenocinol chain, and Rings A, B and C of moenomycin A, and optionally Ring D, to provide a saccharide group of Formula (IV-S1):
    
    






wherein R1, R2, R3, R6, R7, R18, and R12 are as defined herein;

    
    
        (iii) reacting (IV-S1) with a phosphitylation agent to provide an H-phosphonate diester of Formula (IV-S2):
    
    






wherein Ra is as defined herein; and

    
    
        (iv) coupling (IV-S2) with a compound of Formula (P1):
    
    






wherein Rb and G are as defined herein, to provide a compound of Formula (IV), or a pharmaceutically acceptable form thereof.

In certain embodiments, step (ii) of the any of the above methods comprises removing the moenocinol chain, followed by removal of the phosphoglycerate linker.
In certain embodiments, step (ii) comprises removing the moenocinol chain using a Lewis acid. Exemplary Lewis acids include, but are not limited to, AlCl3, BF3OEt3, and TMSOTf.
In certain embodiments, step (ii) comprises removing the phosphoglycerate linker using a base. In certain embodiments, the base is an inorganic base. Exemplary inorganic bases include, but are not limited to, NaOH, KOH, LiOH, Ca(OH)2, Mg(OH)2, Na2CO3, NaHCO3, K2CO3 and KHCO3.
Phosphitylation agents are well-known reagents in the art; see Garegg et al., Chem. Scr. (1985) 25:280-282 and Westerduin et al., Tet. Lett. (1986) 27:6271-6274, incorporated herein by reference. Exemplary phosphitylation agents include, but are not limited to, 2-benzo[d]-1,2-oxaphosphophepin-2,5-dione compounds (e.g., 2-methoxybenzo[d]-1,3,2-dioxaphosphorin-4-one, 2-chloro-benzo[d]-1,3,2-dioxaphosphorin-4-one, 2-R-benzo[d]-1-1,3,2-dioxaphosphorin-4-one), and tris(1,1,1,3,3,3-hexafluoro-2-propyl)phosphite.
In certain embodiments, step (ii) of any of the above methods comprises removing Rings A, B, C and/or D of moenomycin A. In certain embodiments, step (ii) of the above methods comprises first removing Rings A, B, C and/or D of moenomycin A, followed by removing the moenocinol chain, followed by removal of the phosphoglycerate linker. In certain embodiments, the step of removing Rings A, B, C and/or D comprises one or more enzymatic degradative reactions. In certain embodiments, the step of removing Rings A, B, C and/or D comprises a combination of enzymatic degradative and enzymatic synthetic reactions.
Examples of enzymatic degradative reactions are well known in the art; see for example, U.S. Pat. Nos. 5,206,405; 5,260,206; 5,315,038; and 5,506,140, each of which is incorporated herein by reference. For example, the enzymatic degradative step may be catalyzed by an enzyme (e.g., lipase, esterase, transferase, etc.). The enzymatic degradative step may be accomplished using an enzyme, a cell lysate, a cell, a cell culture, or the like. The cell or enzyme may be a wild-type or genetically engineered cell or enzyme.
Examples of enzymatic synthetic reactions useful in preparing the inventive compounds are also known in the art; see for example, WO 2008/021367, incorporated herein by reference. For example, the enzymatic synthetic step may be catalyzed by an enzyme (e.g., lipase, esterase, ligase, synthase, transferase, epimerase, etc.). The enzymatic synthetic step may be accomplished using an enzyme, using a cell lysate, using a cell, using a cell culture, or the like. The cell or enzyme may be a wild-type or genetically engineered cell or enzyme.
In certain embodiments, step (iv) of any of the above methods comprises coupling a H-phosphonate diester with a compound of the formula (P1). In certain embodiments, the method comprises use of a coupling agent used in H-phosphate chemistry; e.g., see Stawinski, In Handbook of Organophosphorus Chemistry, R. Engel (Ed.), pp. 377-434, Marcel Dekker, New York (1992), and Kraszewski and Stawinski, Trends Org. Chem. (2003) 10:1, incorporated herein by reference. Exemplary coupling reagents include, but are not limited to, adamantanecarbonyl chloride and 1,3-dimethyl-2-chloro-imidazolinium chloride (DMCI).
EXAMPLES
In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
Synthetic Methods
Preparation of 2,5-Di-O-Alkyl-D-Mannitol
To a stirred suspension of 60% NaH (3 equiv.), washed twice with petroleum ether, in anhydrous DMF (8 mL/mmol-starting material (SM)) was added 1,3:4,6-di-O,O-(4-methoxybenzylidene)-D-mannitol (1 equiv., SM) at room temperature. After being stirred for 30 min, the mixture was treated with a 1.2 M solution of alkylating reagents (2.4 equiv., Br, Cl, and methane- or p-toluene-sulfonate for R=allyl, benzyl, and n-alkyl groups, respectively) in anhydrous DMF and a catalytic amount of tetrabutylammonium iodide for allyl-Br, bromide for benzyl-Cl, or 15-Crown-5 for n-alkyl sulfonates. The resulting mixture was stirred for 18 h at rt for allyl-Br and benzyl-Cl or 70° C. for n-alkyl sulfonates, and then poured into sat. aq. NH4Cl (8 mL/mmol-SM). The immiscible mixture was extracted twice with Et2O and the combined organic phases were washed with water, brine, dried over MgSO4, and then concentrated in vacuo. The crude ether was used for the next reaction without further purification.
For allyl and benzyl derivatives, a stirred solution of the residue in THF-H2O (4:1, 8 mL/mmol-SM) was treated with AcOH (170 equiv.) at room temperature. After being stirred at 55° C. for 2 d, the mixture was cooled to 0° C. and basified with 4 M aq. K2CO3 (90 equiv.). The immiscible mixture was extracted twice with CHCl3 and the combined organic phases were washed with brine, dried over MgSO4, and then concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether:EtOAc=1:3 to 0:1) to give 2,5-di-O-allyl or benzyl-D-mannitol.
For n-alkyl derivatives, a stirred solution of the residue in EtOH (12 mL/mmol-SM) was treated with 3 M aq. HCl (12 equiv.) at room temperature. After being stirred at 70° C. for 3 h, the mixture was cooled to room temperature and basified with 4 M aq. K2CO3 (16 equiv.). The immiscible mixture was extracted twice with CHCl3 and the combined organic phases were washed with brine, dried over MgSO4, and then concentrated in vacuo. The residue was purified by recrystallization from Et2O/EtOAc to give 2,5-di-O-n-alkyl-D-mannitol.
Preparation of Methyl 2-O-Alkyl-D-Glycerate
To a 5.5 M solution of 2,5-di-O-alkyl-D-mannitol (1 equiv., SM) in THF-H2O (9:1) was added NaIO4 (1.2 equiv.) at room temperature and the mixture was stirred at 50° C. for 1 h. The resulting inorganic salt was removed by filtration through a pad of silica gel and washed with EtOAc. The filtrate was concentrated in vacuo and the crude aldehyde was used for the next reaction.
To a stirred solution of the residue in t-BuOH (20 mL/mmol-SM) were added 2-methyl-2-butene (100 equiv.) and a solution of 80% NaClO2 (12 equiv.) and NaH2PO4. H2O (10 equiv.) in H2O (8 mL/mmol-SM) at 0° C. successively. The resulting yellow mixture was allowed to warm to room temperature for 6 h, during which it turned into clear. Then, the mixture was cooled to 0° C. again and treated with 2.5 M aq. Na2SO3 (25 equiv.) to reduce an excess of NaClO2. The mixture was acidified with 10% aq. citric acid (10 mL/mmol-SM) and extracted twice with CHCl3 and the combined organic phases were washed with brine, dried over MgSO4, and then concentrated in vacuo. The crude acid was used for the next reaction without further purification.
To a stirred solution of the residue in anhydrous THF-MeOH (1:1, 10 mL/mmol-SM) was treated with 2 M TMSCHN2 solution in hexanes (3.2 equiv.) at 0° C. After being stirred for 10 min, the resulting yellow mixture was decolorized by an addition of AcOH (3.2 equiv.) to consume an excess of TMSCHN2. The mixture was concentrated in vacuo and the residue was purified by silica gel chromatography (petroleum ether:EtOAc=4:1 to 3:2) to give methyl 2-O-alkyl-D-glycerate.
Preparation of Methyl 2-O-Fluoroalkyl-D-Glycerate
To a stirred 0.9 M solution of methyl 2-O-(9-decenyl)-D-glycerate (1 equiv., SM), prepared from 1,3:4,6-di-O,O-(4-methoxybenzylidene)-D-mannitol and 9-decenyl p-toluenesulfonate in the above-mentioned 5 steps, in hexane were added perfluorooctyl iodide (1.2 equiv.) and 1 M Et3B solution in hexanes (0.2 equiv.) at room temperature under air. The reaction mixture was stirred at the same temperature for 1.5 h, then perfluorooctyl iodide (0.3 equiv.) and 1 M Et3B solution in hexanes (0.1 equiv.) were added again. After being stirred for 30 min, the solution was diluted with Et2O and poured into a mixture of sat. aq. NaHCO3 and 10% aq. Na2S2O3.5H2O. The mixture was extracted twice with Et2O and the combined organic phases were washed with brine, dried over MgSO4, and then concentrated in vacuo. The crude iodide was used for the next reaction without further purification.
To a solution of the residue in MeOH (10 mL/mmol-SM) were added NaHCO3 (1.5 equiv.) and 10% PdC (mg/mg-SM). The resulting mixture was stirred at room temperature for 13 h under H2 atmosphere (1 atm). PdC was removed by filtration through a pad of Celite and washed with EtOAc. The filtrate was concentrated in vacuo and the residue was purified by silica gel chromatography (petroleum ether:EtOAc=3:1 to 7:3) to give methyl 2-O-fluoroalkyl-D-glycerate.
Preparation of 0.2 M Phosphoramidite Solution
To a 0.2 M solution of methyl 2-O-alkyl-D-glycerate (1 equiv.) in anhydrous CH3CN were added N,N-diisopropylethylamine (1.5 equiv.) and ClP(OCE)Ni—Pr2 (1.2 equiv.) at room temperature successively. The reaction mixture was stirred for 1 h and directly used for the next coupling reaction.
Preparation of Nonaacetyl Moenomycin A Pentasaccharide Phosphate
To a mixture of nonaacetyl moenomycin A pentasaccharide lactol (1 equiv., SM), azeotropically dried from toluene, and flame-dried MS-3A (2.8 g/mmol-SM) was added 0.34 M 1H-tetrazole solution in CH3CN (6 equiv.) at room temperature. After being stirred for 15 min to remove a trace amount of water, the suspension was cooled to 0° C. and treated with 0.2 M phosphoramidite solution in CH3CN (2 equiv.). The reaction mixture was allowed to warm to room temperature for 1 h, cooled to 0° C. again, and then treated with 5.5 M t-BuO2H solution in decane (12 equiv.) to oxidize the resulting phosphite intermediate into the corresponding phosphate. After being stirred below 10° C. for 1 h, the mixture was treated with P(OMe)3 (12 equiv.) to reduce an excess of t-BuO2H. Then, MS-3A was removed by filtration through a pad of Celite and washed with MeOH. The filtrate was concentrated in vacuo and the residue was roughly purified by silica gel chromatography (EtOAc:MeOH containing 0.5% AcOH=7:1 to 4:1) to give nonaacetyl moenomycin A pentasaccharide phosphate.
Moenomycin A Lipid Analogues, Ammonium Salt
To a stirred 6 mM solution of nonaacetyl moenomycin A pentasaccharide phosphate (1 equiv.) in THF-MeOH—H2O (3:1:1) was added 1 M aq. LiOH.H2O (12 equiv.) at 0° C. The reaction mixture was allowed to warm to room temperature for 2.5 h, and then neutralized with DOWEX 50WX2-100 (NH4+ form, 120 equiv.). The resin was removed by filtration with sintered glass funnel and washed with MeOH. The filtrate was concentrated in vacuo and the residue was purified by reversed-phase HPLC (Agilent Technologies 1200 series HPLC instrument (flow-rate: 1.5 mL/min) using a Phenomenex Luna 5 mm C18 column (250×10.0 mm)) to give moenomycin A lipid analogues as a white solid.








N1-[(2-Hydroxy-5-oxo-cyclopenten-1-yl)-(5S)-β-D-galactopyranuronamide]-(1→4)-2-acetamide-2,6-dideoxy-β-D-gluopyranosyl-(1→4)-[β-D-glucopyranosyl-(1→6)]-2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→2)-3-O-carbamoyl-1-O—{[(R)-2-carboxy-2-((2Z,6E,10E)-3,7,11,15-tetramethyl-hexadeca-2,6,10,14-tetraen-1-yloxy)ethoxy]hydroxyphosphoryl}-4-C-methyl-α-D-glucopyranuronamide, Ammonium salt (1b)
Retention time: 28.9 min (1.5 mL/min, gradient 0-60% CH3CN/0.1 wt % aq. NH4HCO3 over 30 min). 1H NMR (400 MHz, CD3OD): δ 5.95 (m, 1H), 5.40 (t, J=6.4 Hz, 1H), 5.12-5.08 (m, 4H), 4.55-4.40 (m, 5H), 4.30-4.11 (m, 8H), 3.92-3.90 (m, 2H), 3.77-3.43 (m, 14H), 3.36-3.22 (m, 2H), 2.54 (s, 4H), 2.10-1.94 (m, 18H), 1.77 (s, 3H), 1.66 (s, 3H), 1.61 (s, 3H), 1.59 (2s, 6H), 1.43 (d, J=5.9 Hz, 3H), 1.24 (s, 3H). 13C NMR (125 MHz, D2O): δ 199.8, 174.7, 174.3, 172.7, 169.9, 158.3, 142.4, 135.8, 135.0, 131.3, 124.6, 124.5, 124.0, 120.7, 110.6, 103.3, 103.1, 102.4, 101.4, 94.6, 83.0, 79.5, 77.7, 76.4, 76.3, 76.0, 74.9, 73.7, 73.2, 73.1, 72.6, 72.4, 72.2, 71.4, 70.7, 69.9, 69.2, 68.6, 66.7, 61.0, 55.9, 55.2, 39.7, 32.0, 30.3, 29.8, 26.7, 26.6, 25.6, 23.4, 22.7, 17.5, 17.0, 15.9, 15.8, 15.2. 31P NMR (162 MHz, CD3OD): δ −1.52. HRMS (ESI) calcd for C64H99N5O34P [M−NH4]+ 1512.5915, found 1512.5899.




N1-[(2-Hydroxy-5-oxo-cyclopenten-1-yl)-(5S)-β-D-galactopyranuronamide]-(1→4)-2-acetamide-2,6-dideoxy-β-D-gluopyranosyl-(1→4)-[β-D-glucopyranosyl-(1→6)]-2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→2)-3-O-carbamoyl-1-O—{[(R)-2-carboxy-2-((2Z,6E)-3,7,11-trimethyl-dodeca-2,6,10-trien-1-yloxy)ethoxy]hydroxyphosphoryl}-4-C-methyl-α-D-glucopyranuronamide, Ammonium salt (1c). Retention time: 28.6 min (1.5 mL/min, gradient 0-45% CH3CN/0.1 wt % aq. NH4HCO3 over 30 min) 1H NMR (400 MHz, D2O): δ 5.79 (m, 1H), 5.42 (m, 1H), 5.16 (m, 2H), 5.03 (d, J=10.2 Hz, 1H), 4.65-4.44 (m, 5H), 4.32-4.11 (m, 8H), 3.95-3.48 (m, 16H), 3.43-3.29 (m, 2H), 2.45 (s, 4H), 2.15-2.02 (m, 14H), 1.78 (s, 3H), 1.69 (s, 3H), 1.62 (2s, 6H), 1.41 (d, J=5.5 Hz, 3H), 1.23 (s, 3H). 13C NMR (125 MHz, D2O): δ 199.8, 175.4, 174.7, 174.4, 172.9, 169.9, 158.3, 143.6, 137.0, 133.5, 124.6, 124.1, 120.3, 110.6, 103.3, 103.0, 102.4, 101.4, 94.6, 83.3, 79.9, 78.1, 76.6, 76.2, 76.0, 75.1, 74.9, 73.7, 73.31, 73.26, 73.0, 72.6, 72.4, 72.2, 71.4, 70.8, 69.9, 69.1, 68.8, 66.7, 66.5, 60.9, 55.9, 55.2, 39.0, 31.5, 30.2, 26.1, 26.0, 25.1, 23.0, 22.6, 22.5, 17.3, 16.9, 15.5, 14.9. 31P NMR (162 MHz, D2O): δ −1.08. HRMS (ESI) calcd for C59H91N5O34P [M−NH4]+ 1444.5289, found 1444.5257.




N1-[(2-Hydroxy-5-oxo-cyclopenten-1-yl)-(5S)-β-D-galactopyranuronamide]-(1→4)-2-acetamide-2,6-dideoxy-β-D-gluopyranosyl-(1→4)-[β-D-glucopyranosyl-(1→6)]-2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→2)-3-O-carbamoyl-1-O—{[(R)-2-carboxy-2-(eicosan-1-yloxy)ethoxy]hydroxyphosphoryl}-4-C-methyl-α-D-glucopyranuronamide, Ammonium salt (1d). Retention time: 27.8 min (1.5 mL/min, gradient 0-80% CH3CN/0.1 wt % aq. NH4HCO3 over 30 min). 1H NMR (400 MHz, CD3OD): δ 5.95 (m, 1H), 5.10 (d, J=10.2 Hz, 1H), 4.55-4.04 (m, 13H), 3.93-3.90 (m, 2H), 3.75-3.24 (m, 16H), 2.54 (s, 4H), 2.05 (s, 3H), 2.03 (s, 3H), 1.64-1.62 (m, 2H), 1.43 (d, J=6.2 Hz, 3H), 1.41-1.28 (m, 34H), 1.24 (s, 3H), 0.89 (t, J=6.8 Hz, 3H). 13C NMR (125 MHz, D2O): δ 199.6, 174.6, 174.4, 172.6, 169.8, 158.3, 110.7, 103.2, 103.1, 102.5, 101.4, 94.7, 82.9, 79.5, 79.1, 76.3, 76.1, 75.0, 73.6, 73.2, 72.4, 72.3, 71.3, 70.7, 69.9, 69.2, 68.5, 66.5, 61.0, 55.9, 55.2, 32.2, 30.1, 30.0, 29.7, 29.3, 26.0, 22.9, 22.7, 17.1, 15.3, 14.2. 31P NMR (162 MHz, CD3OD): δ −1.30. HRMS (ESI) calcd for C64H107N5O34P [M−NH4]+ 1520.6541, found 1520.5525.




N1-[(2-Hydroxy-5-oxo-cyclopenten-1-yl)-(5S)-β-D-galactopyranuronamide]-(1→4)-2-acetamide-2,6-dideoxy-β-D-gluopyranosyl-(1→4)-[β-D-glucopyranosyl-(1→6)]-2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→2)-3-O-carbamoyl-1-O—{[(R)-2-carboxy-2-(octadecan-1-yloxy)ethoxy]hydroxyphosphoryl}-4-C-methyl-α-D-glucopyranuronamide, Ammonium salt (1e). Retention time: 28.8 min (1.5 mL/min, gradient 0-70% CH3CN/0.1 wt % aq. NH4HCO3 over 30 min). 1H NMR (400 MHz, CD3OD): δ 5.99 (m, 1H), 5.09 (d, J=10.2 Hz, 1H), 4.55-4.12 (m, 13H), 3.92-3.89 (m, 2H), 3.80-3.23 (m, 16H), 2.54 (s, 4H), 2.05 (s, 3H), 2.00 (s, 3H), 1.65-1.60 (m, 2H), 1.43 (d, J=5.9 Hz, 3H), 1.38-1.28 (m, 30H), 1.24 (s, 3H), 0.89 (t, J=6.8 Hz, 3H). 13C NMR (125 MHz, D2O): δ 200.0, 174.9, 174.7, 174.4, 172.6, 169.8, 158.3, 110.5, 103.2, 103.1, 102.5, 101.4, 94.7, 83.1, 79.4, 79.2, 76.3, 76.1, 74.9, 73.7, 73.2, 72.4, 72.2, 71.4, 71.2, 70.7, 69.9, 69.2, 68.5, 66.5, 61.0, 55.9, 55.1, 32.2, 30.4, 30.1, 30.0, 29.7, 29.3, 25.9, 22.9, 22.7, 17.0, 15.2, 14.2. 31P NMR (162 MHz, CD3OD): δ −1.45. HRMS (ESI) calcd for C62H103N5O34P [M−NH4]+ 1492.6228, found 1492.5222.




N1-[(2-Hydroxy-5-oxo-cyclopenten-1-yl)-(5S)-β-D-galactopyranuronamide]-(1→4)-2-acetamide-2,6-dideoxy-β-D-gluopyranosyl-(1→4)-[β-D-glucopyranosyl-(1→6)]-2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→2)-3-O-carbamoyl-1-O—{[(R)-2-carboxy-2-(11,11,12,12,13,13,14,14,15,15,16,16,17,17,18,18,18-heptadecafluoro-octadecan-1-yloxy)ethoxy]hydroxyphosphoryl}-4-C-methyl-α-D-glucopyranuronamide, Ammonium salt (1f). Retention time: 32.3 min (1.5 mL/min, gradient 0-70% CH3CN/0.1 wt % aq. NH4HCO3 over 35 min) 1H NMR (400 MHz, CD3OD): δ 5.87 (dd, J=6.0, 3.5 Hz, 1H), 5.06 (d, J=10.6 Hz, 1H), 4.56-4.45 (m, 5H), 4.28-4.06 (m, 8H), 3.92-3.90 (m, 2H), 3.77-3.22 (m, 16H), 2.39 (s, 4H), 2.19-2.05 (m, 2H), 2.03 (s, 3H), 2.01 (s, 3H), 1.66-1.55 (m, 4H), 1.42 (d, J=5.9 Hz, 3H), 1.32-1.28 (m, 12H), 1.24 (s, 3H). 19F NMR (376 MHz, D2O): δ −83.2 (3F), −115.8 (2F), −123.2 (2F), −123.5 (4F), −124.4 (2F), −124.9 (2F), −128.1 (2F). 31P NMR (162 MHz, CD3OD): δ −1.06. HRMS (ESI) calcd for C62H86F17N5O34P [M−NH4]+ 1798.4626, found 1798.4622.




N1-[(2-Hydroxy-5-oxo-cyclopenten-1-yl)-(5S)-β-D-galactopyranuronamide]-(1→4)-2-acetamide-2,6-dideoxy-β-D-gluopyranosyl-(1→4)-[β-D-glucopyranosyl-(1→6)]-2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→2)-3-O-carbamoyl-1-O—{[(R)-2-carboxy-2-(hexadecan-1-yloxy)ethoxy]hydroxyphosphoryl}-4-C-methyl-α-D-glucopyranuronamide, Ammonium salt (1 g). Retention time: 30.2 min (1.5 mL/min, gradient 0-60% CH3CN/0.1 wt % aq. NH4HCO3 over 30 min). 1H NMR (400 MHz, CD3OD): δ 5.97 (m, 1H), 5.09 (d, J=10.6 Hz, 1H), 4.53-4.12 (m, 13H), 3.92-3.89 (m, 2H), 3.77-3.24 (m, 16H), 2.54 (s, 4H), 2.05 (s, 3H), 2.00 (s, 3H), 1.63-1.62 (m, 2H), 1.43 (d, J=6.2 Hz, 3H), 1.40-1.28 (m, 26H), 1.24 (s, 3H), 0.89 (t, J=6.8 Hz, 3H). 13C NMR (125 MHz, D2O): δ 199.7, 175.0, 174.6, 174.4, 172.6, 169.8, 158.3, 110.6, 103.2, 103.1, 102.5, 101.4, 94.7, 83.0, 79.5, 79.3, 76.4, 76.3, 76.1, 75.0, 73.7, 73.2, 73.1, 72.5, 72.4, 72.2, 71.4, 71.2, 70.7, 69.8, 69.2, 68.5, 66.5, 60.9, 55.9, 55.2, 32.1, 30.3, 30.0, 29.9, 29.6, 29.2, 25.9, 22.8, 22.7, 17.0, 15.2, 14.2. 31P NMR (162 MHz, CD3OD): δ −1.54. HRMS (ESI) calcd for C60H99N5O34P [M−NH4]+ 1464.5915, found 1464.5903.




N1-[(2-Hydroxy-5-oxo-cyclopenten-1-yl)-(5S)-β-D-galactopyranuronamide]-(1→4)-2-acetamide-2,6-dideoxy-β-D-gluopyranosyl-(1→4)-[β-D-glucopyranosyl-(1→6)]-2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→2)-3-O-carbamoyl-1-O—{[(R)-2-carboxy-2-(3-((3′-([1,1′-biphenyl]-3-ylmethoxy)-[1,1′-biphenyl]-3-yl)methoxy)phenylmethan-1-yloxy)ethoxy]hydroxyphosphoryl}-4-C-methyl-α-D-glucopyranuronamide, Ammonium salt (1h). Retention time: 33.3 min (1.5 mL/min, gradient 0-60% CH3CN/0.1 wt % aq. NH4HCO3 over 35 min) 1H NMR (400 MHz, D2O): δ 7.31-6.29 (m, 21H), 5.79 (m, 1H), 5.04 (m, 1H), 4.80-3.32 (m, 35H), 2.36 (s, 4H), 2.07 (s, 3H), 2.05 (s, 3H), 1.39 (m, 3H), 1.23 (s, 3H). 13C NMR (125 MHz, D2O): δ 200.2, 174.6, 174.4, 172.5, 169.8, 158.7, 158.3, 156.0, 141.7, 140.6, 140.2, 139.9, 137.5, 137.3, 130.1129.4, 128.7, 126.6, 125.8, 121.4, 119.6, 113.7, 113.3, 113.0, 112.3, 110.4, 103.2, 103.0, 102.4, 101.4, 94.5, 83.1, 79.4, 78.7, 76.2, 76.0, 74.9, 73.6, 73.2, 72.3, 72.2, 71.3, 70.7, 69.8, 69.1, 68.5, 66.7, 60.9, 55.8, 55.1, 30.4, 22.7, 17.0, 15.2. 31P NMR (162 MHz, D2O): δ −1.07. HRMS (ESI) calcd for C77H93N5O36P [M−NH4]+ 1694.5343. found 1694.5324.




N1-[(2-Hydroxy-5-oxo-cyclopenten-1-yl)-(5S)-β-D-galactopyranuronamide]-(1→4)-2-acetamide-2,6-dideoxy-β-D-gluopyranosyl-(1→4)-[β-D-glucopyranosyl-(1→6)]-2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→2)-3-O-carbamoyl-1-O—{[(R)-2-carboxy-2-(3-((3′-(benzyloxy)-[1,1′-biphenyl]-3-yl)methoxy)phenylmethan-1-yloxy)ethoxy]hydroxyphosphoryl}-4-C-methyl-α-D-glucopyranuronamide, Ammonium salt (1i). Retention time: 27.8 min (1.5 mL/min, gradient 0-60% CH3CN/0.1 wt % aq. NH4HCO3 over 30 min) 1H NMR (400 MHz, CD3OD): δ 7.62-7.19 (m, 14H), 7.02-6.96 (m, 3H), 5.90 (dd, J=6.2, 3.3 Hz, 1H), 5.17 (s, 2H), 5.14 (s, 2H), 5.07 (d, J=10.6 Hz, 1H), 4.87-4.09 (m, 13H), 3.91-3.88 (m, 2H), 3.73-3.21 (m, 16H), 2.35 (s, 4H), 2.01 (s, 3H), 1.99 (s, 3H), 1.36 (d, J=6.2 Hz, 3H), 1.24 (s, 3H). 13C NMR (125 MHz, D2O): δ 200.5, 175.0, 174.6, 174.4, 172.5, 169.9, 158.7, 158.3, 156.1, 141.7, 140.3, 137.6, 136.6, 130.2, 129.4, 128.5, 127.9, 127.4, 126.6, 126.4, 125.9, 125.5, 121.4, 119.7, 113.6, 112.5, 110.3, 103.2, 103.1, 102.4, 101.4, 94.5, 83.2, 79.5, 78.9, 76.4, 76.2, 76.0, 75.0, 74.9, 73.7, 73.2, 73.1, 72.5, 72.4, 72.2, 71.3, 70.8, 69.8, 69.6, 69.1, 68.5, 67.1, 66.8, 60.9, 55.8, 55.2, 30.4, 30.2, 16.9, 15.1. 31P NMR (162 MHz, CD3OD): δ −0.98. HRMS (ESI) calcd for C71H89N5O36P [M−NH4]+ 1618.5030, found 1618.5003.




N1-[(2-Hydroxy-5-oxo-cyclopenten-1-yl)-(5S)-β-D-galactopyranuronamide]-(1→4)-2-acetamide-2,6-dideoxy-β-D-gluopyranosyl-(1→4)-[β-D-glucopyranosyl-(1→6)]-2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→2)-3-O-carbamoyl-1-O—{[(R)-2-carboxy-2-(3-((3′-methyl-[1,1′-biphenyl]-3-yl)methoxy)phenylmethan-1-yloxy)ethoxy]hydroxyphosphoryl}-4-C-methyl-α-D-glucopyranuronamide, Ammonium salt (1j). Retention time: 28.1 min (1.5 mL/min, gradient 0-50% CH3CN/0.1 wt % aq. NH4HCO3 over 30 min)
Example 1
A 96 well plate with 100 μL test medium in all wells was prepared by handheld multipipettor. A stock solution of the antibiotic or compound in DMSO (0.05 ̃10 mg/mL, 5 μL) and the same medium (95 μL) were put together into column one, where the compound concentration doubled the highest one to be tested. Two columns were necessary for each compound to check the reproducibility. The compound was diluted by adding 100 μL from column one to column two with a 50% volume mix done three times; diluting serially across the plate was continued.
The day before the assay was scheduled to be run, strains were suspended in the test media (Brain Heart Infusion (BHI) containing 0.1% casamino acids for S. aureus, S. epidermidis, and E. faecalis, Trypticase Soy Broth (TSB) containing 5% sheep blood for S. pneumoniae, and Lysogeny Broth (LB) for E. coli) and incubated overnight at 35-37° C. The suspension was diluted with the same media to 1%, 100 μL of which was added to each well of the MIC plate. The MIC plate was incubated at 35-37° C. for 20 h. A thiazolyl blue tetrazolium bromide (MTT) solution (1 mg/mL-water, 50 μL) was added into each well and the resulting MIC plate was incubated at 35-37° C. for a few hours to stain wells in which cell proliferated. Growth is also visible as any turbidity in wells. MIC was defined as the lowest antibiotic concentration that resulted in no growth after the incubation. See Table 1.
Example 2
Curtailing the tail portion of Moenomycin A (MmA) led to shorter half-life. Following IV (2 mpk) and SC (10 mpk) administration, significant systemic exposure to CB-186295 (Moenomycin A) was observed. The compound exhibited biphasic kinetics with distribution phase followed by elimination phase. The % SC bioavailability was 89%. The half-life following IV and SC administration were 8.7 and 7.5 days, respectively (NCA analysis). The clearance following IV administration was very low leading higher exposure (3 mL/hr/kg) and volume of distribution (Vss) was 0.5 L/kg. See Table 2.












TABLE 1






S. aureus
S.
E.
S.




13709
epidermidis
faecalis
pneumoniae
E. coli



25923
1228
29212
6303
MG1655



13709
700562
33186
#1629
NR698







Vancomycin•HCl
3.9
2.0
3.9
 0.49
250  



3.9
3.9
2.0
 0.49
 0.49



2.0






 






 0.16  0.16  0.078
 0.16  0.16
 0.16  0.16
1.3 1.3
31    0.0098


 






3.9 3.9 2.0
2.0 2.0
3.9 3.9
2.0 3.9
63   0.061


 






>250   >250   250  
>250   >250  
250   >250  
63  31 
>250    0.98


 






1.3  0.63  0.63
 0.63 1.3
 0.63  0.63
2.0 3.1
7.8   0.0049


 






2.0  0.98  0.98
 0.49  0.49
 0.49  0.98
3.9 3.9
63    0.0024


 






3.9 2.0 2.0
 0.98 2.0
 0.98 2.0
2.0  0.98
250   >0.16


 






16  16  16 
16  31 
31  16 
16  16 
250    0.16


 






 0.39  0.20  0.20
 0.20  0.20
 0.39  0.78
 0.98 2.0
125    0.039


 






7.8 7.8 7.8
3.9 7.8
16  32 
3.9 7.8
>250    0.49


 






>250   >250   >250  
125   >250  
>250   >250  
16  16 
>250    0.98
















TABLE 2


































*dose solution not analyzed to determine exact dose


**R2 > 0.9 for elimination rate constant






EQUIVALENTS AND SCOPE
Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, but rather is as set forth in the appended claims.
In the claims articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.
Furthermore, the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim.
Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements and/or features, certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements and/or features. For purposes of simplicity, those embodiments have not been specifically set forth in haec verba herein. It is also noted that the terms “comprising” and “containing” are intended to be open and permits the inclusion of additional elements or steps.
Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.
This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the incorporated references and the instant specification, the specification shall control.
In addition, any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the claims. Because such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the invention can be excluded from any claim, for any reason, whether or not related to the existence of prior art.
The foregoing has been a description of certain non-limiting embodiments of the invention. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present invention, as defined in the following claims.

## Claims

1. A compound of Formula (I):



or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, isomer, enantiomer, diastereomer, or polymorph thereof;
wherein:
G is a group of Formula (a), (b), or (c):





wherein a is 3, 4, or 5;




wherein:
X1, X2, X3, X4, X5, X6, and X7 are each independently hydrogen or halogen;
d is an integer between 1 and 25, inclusive; and
e is an integer of between 2 and 25, inclusive;
provided that at least one of X1, X2, X3, X4, X5, X6, and X7 is halogen; and
the sum of d and e is greater than 16;

or




wherein:
Y is —O—, —S—, —NRY—, or an optionally substituted methylene group, wherein RY is hydrogen, optionally substituted aliphatic, or an amino protecting group;
each instance of Rc is independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORe, —SRe, —NHRe, or —N(Re)2, wherein each instance of Re is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two Re groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;
each instance of Rd is independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORf, —SRf, —NHRf, or —N(Rf)2, wherein each instance of Rf is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two Rf groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;
Rz is hydrogen, —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORg, —SRg, —NHRg, or —N(Rg)2, wherein each instance of Rg is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl or two Rg groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;
each instance of n is, independently, 0, 1, 2, 3, or 4;
each instance of m is, independently, 0, 1, 2, 3, or 4; and
x is 1, 2, 3, 4, 5, or 6;
Rxx is hydrogen, a hydroxyl protecting group, or a group of Formula:




R12 is hydrogen, a hydroxyl protecting group, or the group (D):




wherein R13, R14, R15,  R16, and R17 are each independently hydrogen or a hydroxyl protecting group;
R1, R2, R3, and R4 are each independently hydrogen or an amino protecting group;
R5 is hydrogen, an amino protecting group, or the group (A):




R6, R7, R8, R9, R10, and R11 are each independently hydrogen or a hydroxyl protecting group; and
Ra and Rb are each independently hydrogen or a hydroxyl protecting group.

2. The compound of claim 1 of Formula (II):



or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, isomer, enantiomer, diastereomer, or polymorph thereof.

3. The compound of claim 1 of Formula (III):



or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, isomer, enantiomer, diastereomer, or polymorph thereof; wherein R17 is hydrogen or a hydroxyl protecting group.

4. The compound of claim 1 of Formula (IV):



or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, isomer, enantiomer, diastereomer, or polymorph thereof; wherein R18 is hydrogen or a hydroxyl protecting group.

5. The compound of claim 1 wherein G is a group of Formula (a).

6. The compound of claim 5, wherein the group of Formula (a) is selected from the group consisting of:

7. The compound of claim 1 wherein G is a group of Formula (b).

8. The compound of claim 7 wherein at least one of X1, X2, X3, X4, X5, X6, and X7 is halogen.

9. The compound of claim 7 wherein X1 and X2 are each hydrogen, X3 and X4 are each fluoro, and X5, X6, and X7 are each fluoro.

10. The compound of claim 7, wherein the group of Formula (b) is selected from the group consisting of:

11. The compound of claim 1 wherein G is a group of Formula (c).

12. The compound of claim 11, wherein the group of Formula (c) is selected from the group consisting of:























wherein:
Rc1, Rc2, Rc3, Rc4, Rc5, and Rc6, each independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORe, —SRe, —NHRe, or —N(Re)2, wherein each instance of Re is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two Re groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;
Rd1, Rd2, Rd3, Rd4, Rd5, and Rd6, each independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORf, —SRf, —NHRf, or —N(Rf)2, wherein each instance of Rf is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two Rf groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;
Y1, Y2, Y3, Y4, Y5, and Y6, each independently corresponds to —O—, —S—, —NRY—, or an optionally substituted methylene group, wherein RY is hydrogen, optionally substituted aliphatic, or an amino protecting group;
n1, n2, n3, n4, n5, and n6 each independently 0, 1, 2, 3, or 4; and
m1, m2, m3, m4, m5, and m6 each independently 0, 1, 2, 3, or 4.

13. The compound of claim 1 wherein G is selected from the group consisting of:

14. A pharmaceutical composition comprising an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, isomer, enantiomer, diastereomer, or polymorph thereof, and optionally a pharmaceutically acceptable excipient.

15. A method of treating a bacterial infection comprising administering to a subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, isomer, enantiomer, diastereomer, or polymorph thereof.

16. The method of claim 15, wherein the bacterial infection being treated is caused by Gram-positive bacteria.

17. The method of claim 15, wherein bacterial infection being treated is caused by Gram-negative bacteria.

18. The method of claim 15, wherein bacterial infection being treated is caused by vancomycin-resistant bacteria.

19. The method of claim 15, wherein bacterial infection being treated is caused by methicillin-resistant bacteria.

20. An in vitro method of inhibiting bacterial growth by contacting a bacterium with an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, isomer, enantiomer, diastereomer, or polymorph thereof.

21. The method of claim 15, wherein the bacterial infection being treated is caused by vancomycin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci, or methicillin-resistant Staphylococcus aureus.

22. The compound of claim 1, wherein the compound is of Formula (I):



or a pharmaceutically acceptable salt.

23. A pharmaceutical composition comprising an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

24. A method of treating a bacterial infection comprising administering to a subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.